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ABSTRACT OF THE DISSERTATION

Regulation and Function of TREM2-dependent Pathways in Neurodegeneration
by
Wilbur M. Song
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2020
Professor Marco Colonna, Advisor
Carriers of the R47H allele of the microglia-specific lipid receptor TREM2 have a greatly
increased risk of developing Alzheimer’s disease. The objective of this dissertation is to develop
further mechanistic knowledge about how TREM2 is regulated and how TREM2 mutations affect
microglia and neurodegeneration. Using an in vitro reporter assay, we find that several AD riskassociated TREM2 mutations decrease ligand-dependent activation. Using humanized TREM2
mice, we find that in vivo, the R47H mutation leads to reduced microglia activation and response
to Aβ, as well as decreased shedding of soluble TREM2. These results suggest that TREM2 is
protective during disease. We find that TREM2-deficient macrophages in vitro are more
susceptible to stress-induced loss of mTOR signaling, increased autophagy, and low-energy status.
In vivo, microglia similarly fail to maintain mTOR signaling and increase autophagy in an Aβ
mouse model, which could be rescued by enhancing energy utilization with long-term
cyclocreatine supplementation. These results suggest that TREM2 is playing a fundamental role
in maintaining microglia health and survival rather than triggering a specific activation signature.
Finally, we perform an unbiased CRISPR-Cas9 knockout screen to identify and characterize
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pathways that regulate TREM2 surface expression, identifying TMEM131 as a suppressor of
TREM2 surface expression. We further demonstrate that TMEM131 regulation of TREM2 does
not involve cleavage or degradation of TREM2 from the cell surface or require the unique
intramembranous charge of TREM2. These results provide a stepping stone for identifying novel
therapeutic targets related to TREM2.
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Chapter 1: Introduction
1.1 Microglia at rest
Studies of the role of the immune system in neurological diseases have long been confined
to grossly neuroinflammatory conditions such as infection, stroke, and certain autoimmune
diseases. However, emerging evidence implicates immune function in a variety of chronic
neurodegenerative diseases1–5. In these cases, immune responses do not feature profuse
inflammatory infiltrates but rather local responses by resident cells. While neurons and astrocytes
do respond to various cytokines, the primary dedicated immune cell and most likely coordinator
of immune responses in the central nervous system (CNS) is the microglia, an embryonically
derived6, self-renewing7–9 tissue macrophage. In addition to other common myeloid lineage factors
such as PU.110, microglia maturation requires the lineage-specific transcription factors Irf811 and
Sall112 and input from the gut microbiota13,14 and CNS microenvironment. The confluence of these
factors generates a unique transcriptional signature, including surface receptors such as P2ry12,
Fcrls, Siglec H, Tmem119, and Trem2; and transcription factors such as Sall1, Sall3, Zfp691, and
Smad7. As with other tissue macrophages, microglia also express CX3CR1, Mer, and Fcgr115.
Recent studies examining isolated live human microglia for the first time revealed overall
similarity between mouse and human microglia, with higher expression of some immune
activation-associated genes such as MHCII, which may reflect genetically encoded or experiential
differences16,17.
To maintain their unique transcriptional identity, microglia require continuous signals
from the microenvironment, as evidenced by the observation that culturing primary adult
1

microglia rapidly downregulates key microglia genes on the transcriptional and protein level17–19.
One of the brain-derived signals required for the microglia signature is TGFβ, as demonstrated by
genetic TGFβ deficiency studies, and supplementing cultured microglia with TGFβ can partially
restore microglia-specific gene expression12,18. Recent attempts to differentiate microglia from
pluripotent stem cells found that coculturing stem cell-derived microglia with neurons and
astrocytes could achieve greater similarity to microglia in situ20–22, suggesting that a complex
mixture of cell-cell interactions and paracrine signaling shapes the microglia identity. Notably, the
brain microenvironment is also not sufficient to fully recapitulate microglia gene expression, as
peripherally monocytes forced to enter the brain do not fully adopt the homeostatic microglia
signature23,24. During homeostatic conditions, the tight dependence on microenvironment leads to
subtle differences between microglia in different brain regions25. However, in settings of
neuropathology, the brain microenvironment becomes highly perturbed locally, and this could
lead both to positive and negative signals that activate microglia. TGFβ is classically thought of
as an anti-inflammatory cytokine, and loss of TGFβ signaling would be expected not only to
disrupt the resting microglia signature but also to promote inflammatory responses by microglia.
The enhanced understanding of fundamental microglia biology during development and
homeostasis over the past few years has helped to contextualize microglia responses to
pathological insults. Thus, while “microgliosis” has long been noted as a component of
neuropathology, more mechanistic models of microglia function during disease are only now being
fleshed out.
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1.2 A common microglial response to neuropathology
Microglia proliferate and change morphology in response to neurodegenerative disease, a
process referred to as “microgliosis”. In post-mortem Alzheimer’s disease (AD) specimens,
reactive microglia are found in abundance surrounding amyloid beta (Aβ) plaques26, and recent omics studies in human brain have revealed that microglial changes constitute the strongest
transcriptional and epigenetic signal of AD and normal aging27–30. Reactive microglia also increase
in Parkinson’s disease31 (PD) and Huntington’s disease (HD) brains32,33. Accordingly, animal
models of both amyloid accumulation and tauopathy, the two pathological hallmarks of AD,
feature similar changes in the microglia population34,35, as do MPTP-induced parkinsonism36 and
amyotrophic lateral sclerosis (ALS)37 models. For many years, these degeneration- or diseaseassociated microglia (DAM) were vaguely described as having less ramified, more amoeboid
morphology and expressing general macrophage activation markers such as MHCII and CD11c.
The development of techniques to isolate microglia and perform genome-wide transcriptomic
analysis has allowed finer characterization of DAM38. Remarkably, DAM have a conserved
transcriptional signature across standard neurodegeneration mouse models including Aβ-driven
APP-Swe/PS1dE9 and 5XFAD mice39–41, the P301S model of tauopathy42, the SOD1G93A model
of ALS43, and the CK-p25 AD model44. This signature includes both classical M1 and M2 genes,
as well as interferon response, stress response, lysosome, and lipid metabolism modules.
Upregulated genes include Axl, Clec7a, Cst7, Spp1, Gpnmb, Lgals3, Apoe, and Trem2, among
many others. Surface proteins such as CD11c, MHCII, CD44, CD14, CD86, CD39, CD90, and
CD274 (PD-L1) are also upregulated in DAM and have been validated on the protein level by
mass cytometry45,46. Conversely, homeostatic microglia signature genes are downregulated.
3

Although shared between neurodegeneration models, the DAM signature is not simply a
generalized response to any stimulus. Microglia populations during experimental autoimmune
encephalitis, which involves profuse inflammatory infiltrates, have distinct surface marker,
cytokine, and signaling profiles compared to neurodegeneration models45,46; and systemic
lipopolysaccharide (LPS) injection, which causes acute neuroinflammation, leads to an overall
different signature47. Several meta-analyses of microglia gene expression datasets have also
pointed out distinctions between neuroinflammatory and neurodegenerative microglia
responses42,47.
One important question is whether the DAM compartment consists of a single cell state or
of multiple distinct populations of M1, M2, and other subsets. Single-cell RNA-seq analysis of
microglia in 5XFAD and CK-p25 mice showed that DAM coordinately acquire the entire DAM
signature and form a heterogeneous but nonetheless singular population by unbiased clustering
analysis44,48. Subset analysis of DAM has also been informed by several large-scale mass
cytometry studies. While these studies were powerful enough to distinguish meningeal
macrophages, perivascular macrophages, and peripheral monocytes in addition to microglia, they
also failed to identify multiple subsets of DAM45,46. One study did distinguish relatively minor
subsets of CD44+ and CXCR4+ DAMs by flow cytometry, arguing for segregation of at least some
DAM modules49. Moreover, in the CK-p25 study, within the DAM cluster certain type I interferonand type II interferon-induced genes were inversely correlated, hinting at subtle differences due
to local signals. Thus, DAM likely comprise a single population with some heterogeneity. It
remains to be seen whether the most dissimilar DAM have consequential differences in function
in vivo.
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While the DAM signature has been best defined using AD and ALS models, it appears in
non-neurodegenerative states. Some examples include cuprizone-induced demyelination50; aged
mice47 and the Ercc1-deficiency model of DNA damage-accelerated aging51; and acute facial
nucleus degeneration after facial nerve axotomy8. The DAM signature is found 16 hours after
intracranial injection of apoptotic neurons52. Perhaps most surprisingly, a DAM-like population is
found in myelin-rich brain regions during the first postnatal week in wild-type mice53. Thus, the
DAM state may represent a relatively rapid response to a set of stimuli that happen to accrue in
aging and chronic disease and transiently during development. But what might these stimuli be?
Tau, SOD1, and axotomy models cause widespread neuron-intrinsic cell death. Cuprizone
treatment induces oligodendrocyte death and accumulation of myelin debris. Both aging and
development present a combination of apoptotic cells and disordered myelin. DAM may be
responding to apoptotic cells specifically; more generally to certain lipidic structures including
apoptotic cells but also myelin or protein aggregate-associated apolipoproteins; or even more
generally to phagocytosis of any endogenous materials via lysosomal signaling. Either way, the
DAM signature seems to be induced by various brain-intrinsic injuries in the absence of massive
peripheral infiltrates and can occur on acute to chronic timescales.

TREM2 and downstream targets are required for DAM induction
The pathway that has been most directly linked to DAM activation is the triggering receptor
expressed on myeloid cells 2 (TREM2) pathway. Naive TREM2-deficient mice have only very
mild differences in microglia transcriptome, morphology, and frequency; however, TREM2deficient 5XFAD microglia fail to upregulate most DAM genes in response to Aβ50. On a single5

cell level, very few TREM2-deficient microglia activate to the full extent of wild-type DAM,
suggesting that TREM2 deficient cells are inherently limited in activation capacity48. A similar
dependence of DAM induction on TREM2 was found with cuprizone-induced demyelination50,
P301S54, SODG93A 52, and apoptotic neuron injection models52. To the contrary, TREM2 deficiency
does not block the inflammatory response to endotoxin in vivo55 and enhances NFκB responses in
vitro56. Thus, TREM2 function seems to be significant specifically in the context of DAM
induction. Microglia in kainate-induced acute neurodegeneration57 and prion disease58 are also
affected by TREM2 deficiency, suggesting that these models also induce DAM.
Once the DAM signature has been engaged, certain upregulated molecules may form an
autocrine or paracrine loop to sustain it. ApoE is one of the most highly-expressed DAM genes.
Total ApoE deficiency reduces the DAM signature in Aβ models52,59, and total knockout or
conditional knockout in microglia reduces the DAM signature after acute apoptotic neuron
injection52, although not as strongly as TREM2 deficiency. These results are consistent with
reports that ApoE and clusterin, or ApoJ, are ligands for TREM260–62, and may hint that ApoE is
one of the primary TREM2 ligands in the brain during neurodegeneration. TREM2 is also
upregulated in DAM, furthering an ApoE-TREM2 positive feedback loop. Another potential
source of positive feedback is CSF-1 upregulation in DAM. This may locally boost CSF1R
signaling, which overlaps with and interacts with TREM2 signaling63. The secreted DAM
molecule Spp1 is a ligand for the DAM-expressed receptor CD4464, representing another potential
loop. Another DAM gene that shapes the DAM signature is miR-15565, which is upregulated in
SOD1G93A microglia dependent on both TREM2 and ApoE and promotes loss of homeostatic
microglia gene expression.
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1.3 Functions of DAM during neurodegenerative disease
Given the emerging consensus that microglia respond robustly to neurodegenerative
disease, much effort has been expended attempting to determine whether microglia are “good” or
“bad” in different diseases. Despite some contradictory reports, several mechanisms have been
delineated by which microglia can impact disease progression in both positive and negative ways.
Because of the conserved nature of the microglia activation signature, it is highly likely that
microglia perform similar functions in diverse disease states, with different outcomes depending
on the model.

Modulation of pathological protein aggregates
Countless studies have been conducted with amyloid burden as an endpoint in AD models.
Increased production of Aβ is a likely driver of familial forms of early-onset AD66,67. On the other
hand, Aβ accumulation in late-onset AD appears to be driven by decreased clearance of Aβ. In the
PS1-APP mouse model, microglia decreased expression of scavenger receptors (SRs) and Aβdegrading proteinases with age68. More significantly, metabolic labeling of Aβ and Aβ1-42 in a
small cohort of human AD and control subjects revealed that the production to clearance ratio was
imbalanced in AD but not control subjects, and this imbalance was driven by a relative decrease
in clearance69. Mechanisms of microglia-mediated Aβ clearance have been extensively reviewed,
and only select studies will be discussed here70–72. Early studies identified the scavenger receptor
CD36 and various TLRs as putative Aβ receptors on microglia that could direct phagocytosis of
fibrillar plaques and demonstrated that deficiency of CD36 increased Aβ accumulation73–75.
7

TREM2 has also been proposed as a receptor for Aβ/lipoprotein complexes that can directly
promote phagocytosis and degradation of Aβ60, although the effect of modulating TREM2 on Aβ
levels in vitro and in vivo is not consistent. Interestingly, several studies have called into question
whether physiological microglia function leads to a net decrease in amyloid, at least in the setting
of commonly used mouse models. In two similar studies, resident microglia were eliminated using
genetic ablation systems that resulted in influx of peripherally-derived myeloid cells. These
infiltrating cells could partially but not fully recapitulate features of resident microglia. Neither
study found a significant effect on Aβ levels of replacing resident microglia with peripherallyderived microglia76,77. Even near-complete depletion of microglia using a small molecule inhibitor
of CSF1R did not alter Aβ levels in 10-month old 5XFAD mice after a month of treatment78.
Lower-dose CSF1R inhibition over a longer period of time gave similar results79, and one study
found that depletion starting from an early age dramatically reduced Aβ accumulation80.
Despite these findings, other reports suggest that microglia have a latent ability to clear Aβ
when inhibitory signals are removed or exogenous activating signals are applied. Viral
overexpression of pro-inflammatory cytokines IFNγ, TNFα, or IL-6 could drive microglia
proliferation and activation with concomitant Aβ reduction81–83. Consistent with general microglia
activation reducing Aβ loads, deficiency of the anti-inflammatory cytokine IL-10 decreased Aβ
level while overexpression increased Aβ level84,85. Several recent translational studies have also
highlighted the potential of boosting microglia function as a therapeutic option to reduce Aβ loads.
A promising clinical study demonstrated that monthly systemic administration of the novel antiAβ antibody aducanumab could reduce Aβ levels in early AD patients, as detected by amyloid
PET scan. Parallel experiments in an Aβ-driven mouse model showed that aducanumab-treated
mice had fewer plaques as well as more microglia around plaques, suggesting that the Aβ reduction
8

was mediated by microglial Fc receptor engagement of the antibody86. A few more exotic
therapeutic options have been explored for reducing Aβ levels via microglia activation. Repeated
scanning ultrasound treatments of the brain could reduce Aβ loads, hypothetically by making
microbubbles that disrupt the blood-brain barrier and subsequently change the microglia
phenotype. This treatment increased the amount of Aβ colocalized with microglia lysosomes,
suggesting that increased phagocytosis was responsible for the differences 87. In another unusual
approach, Aβ-bearing mice were optogenetically stimulated in the hippocampus with a 40 Hz
signal, within the frequency range that appears most disrupted in AD patients. Stimulation at this
frequency altered microglia morphology and increased microglia volume in the hippocampus,
which corresponded to increased colocalization of plaques and microglia and decreased overall
plaque load. Similar results were obtained in the visual cortex when mice were exposed
noninvasively to 40 Hz light flickering88. While 40 Hz entrainment signals reduced Aβ, other
frequencies increased Aβ, so these results should be applied with caution, even if the 40 Hz
frequency was chosen a priori.
Another way microglia may interact with Aβ is by forming a barrier around Aβ plaques
that reduces exposure of nearby neurons and astrocytes to soluble and insoluble Aβ and thereby
protects them. Plaque-associated microglia show polarization of phosphotyrosine and microglia
receptor staining to the plaque-adjacent surface, and microglia processes cover much of the plaque.
In models of deficient plaque-associated microglia such as TREM2 and DAP12 knockout mice,
fibrillar Aβ plaques are looser and have higher surface area by confocal and super-resolution
microscopy. Correspondingly, dystrophic neurites are more frequent surrounding these less tightly
condensed plaques both in mouse and human AD89. A similar phenotype has been observed in
ApoE-deficient APPPS1-21 and APP-Swe/PS1-dE9 mice, which also have a diminished DAM
9

response and decreased microglia localization to plaques. While the total number of fibrillar
plaques is dramatically decreased, which is consistent with prior work on ApoE deficiency, the
remaining plaques are morphologically less compact, have fewer adjacent microglia, and have
correspondingly more surrounding dystrophic neurites on a per-plaque basis59. Further
experimental manipulations of microglia, such as depletion, are required to pin down whether
plaque compaction is a general feature of microglia localization to plaques.

Elimination of synapses and neurons
During development, microglia are essential both for proper pruning of neuronal synapses
and for efferocytosis of normally occurring apoptotic neurons. However, both of these functions
may go into overdrive during neurodegeneration, leading to excessive loss of neurons and synapses
that precipitates or worsens cognitive decline. Synaptic pruning by microglia is dependent on
classical complement components90–92 and is modulated by both neuronal activity and CX3CR1CX3CL1 interaction93,94. In the J20 AD mouse model, this pruning process was shown to be
overactive at an early time point preceding plaque deposition and microglia proliferation, with
increased presence of complement component C1q and decreased overall numbers of synapses in
the hippocampus. Abrogating new production of soluble Aβ with a γ-secretase inhibitor
dramatically decreased the amount of C1q, suggesting that the presence of complement tracks with
that of soluble Aβ. These findings were repeated using an oligomeric Aβ injection model, and with
this system the authors showed that mice deficient in either C1q or the microglia receptor
CR3/CD11b did not lose synapses in response to oligomeric Aβ95.
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Complement-dependent loss of synapses has also been reported in various other
neuropathological models. Another study observed pronounced synapse loss in CA3 of the
hippocampus along with some neuron loss in aged mice compared to young mice. These agerelated changes were largely absent in C3-deficient mice. Furthermore, C3-deficient aged mice
showed lower anxiety and better learning by behavioral testing than wild-type aged mice96. A
histological examination of Huntington’s disease brain specimens found that complement
components are also significantly elevated in this disease relative to control brains, and by in-situ
hybridization these components seemed to be produced by microglia, suggesting that a similar
phenomenon may occur in Huntington’s disease97. Clearly, in a variety of settings, activation of
the complement cascade can lead to synapse loss. One aspect of this pathway that remains to be
clarified is whether increased complement activity on synapses in the diseased state results solely
from higher concentrations of complement components overall or also results from increased
affinity of synapses for complement. The former is supported by upregulation of complement on
the transcriptional level in microglia, and indeed, complement components are prominently
expressed in DAM.
Along these lines, microglia activation in general has been linked to heightened neuron
loss or cognitive impairment in several studies, although in many cases it is unclear which
microglia functions are responsible. Broad inhibition of microglia function can be protective of
neuronal function in certain settings. Pharmacological depletion of microglia with a CSF1R
antagonist somewhat recovered performance in different behavioral tests in 3xTg and 5XFAD AD
mice78,79 and decreased neuron and dendritic spine loss in 5XFAD mice. Treatment with the same
CSF1R antagonist in a model of cranial irradiation rescued memory deficits associated with
irradiation98. Analogous results have been obtained with manipulations that do not ablate microglia
11

but prevent full microglia activation and may represent a specific block of DAM function. In one
study, DAP12 deficiency led to recovery of electrophysiological measures and cognitive function
in APP/PS1 mice99, and TREM2 deficiency dramatically reduced hippocampal atrophy and neuron
loss in the P301S model of tauopathy54.
In addition to pruning synapses, microglia engulf apoptotic neurons during development
via the TAM receptors (Tyro3, Axl, and Mer) that recognize phosphatidylserine directly or
indirectly. While Mer is expressed in homeostatic microglia, Axl is upregulated during pathology,
including in DAM. In the absence of these receptors apoptotic cells accumulate in the brain.
Surprisingly, TAM receptor-deficient mice also accumulate additional live neurons in the olfactory
bulb, suggesting that microglia can also engulf certain live neurons with exposed
phosphatidylserine, such as stressed neurons. The authors of this study proposed that phagocytosis
of stressed neurons could accelerate neurodegeneration, and to support this hypothesis, they
demonstrated that mice deficient in both Axl and Mer had a modest increase in survival in the
Thy1-SynhA53Ttg model of Parkinson’s disease100. This mechanism has also been supported by live
imaging of microglia and neurons in 3xTg mice, which found that microglia tended to colocalize
with neurons that subsequently disappeared, hinting that they had been phagocytosed or killed by
those microglia. Taken together, an abundance of studies have showed that blocking microglia
function during disease can reduce synapse and neuron loss and cognitive decline.
The ability of microglia to exacerbate neurodegeneration was reinforced by several
fascinating studies showing spontaneous neurodegeneration attributed to microglia-intrinsic
disturbances. These studies demonstrate that microglia overactivity is sufficient to cause
neurodegeneration. Microglia deficiency of NRROS, a gene that is thought to negatively regulate
12

ROS production, leads to loss of the homeostatic microglia signature, including the master
regulator Sall1. In NRROS-deficient mice, the predominant myeloid cells in the brain instead
express many markers of perivascular macrophages. Temporally controlled conditional knockout
experiments established that NRROS is required during development and its absence leads to
sustained alterations in microglia identity. Starting at around 3-4 months of age, these mice
develop a progressive, lethal neurodegenerative disease with motor deficits101. In a completely
different system, constitutive activation of the MAPK pathway in microglia was established by
inducible expression of constitutively active Braf V600E. This manipulation causes microglia
proliferation and activation in various regions of the brain and, as with NRROS deficiency, leads
to a neurodegenerative phenotype characterized by synapse and neuron loss, motor deficits, and
death with approximately the same time course102. Finally, a model of CNS TGFβ deficiency that
disrupts the homeostatic microglia signature also led to motor deficits starting, once again, at
around 4 months of age18. However, this particular result is confounded by presumably decreased
TGFβ signaling in neurons, which is important for neuron survival103; in addition, microglia were
relatively depleted, even though remaining microglia did lack the homeostatic microglia signature
and appeared more activated. Other examples of microglia activation possibly being sufficient to
cause neurodegeneration are the interferonopathies discussed in the previous section. Thus,
microglia strongly activated in certain ways can initiate neuron loss and neurodegeneration without
other pathological inputs.
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1.4 Genetic implication of microglia in neurodegeneration
Rare neurological diseases driven by loss of microglia
The most striking genetic implication of microglia in neurodegenerative disease was the
identification of homozygous loss-of-function mutations in TREM2, or its required adaptor for
trafficking and signaling DAP12, as the cause of Nasu-Hakola disease104,105. This condition is an
extremely rare, lethal autosomal recessive disease involving formation of bone cysts and then
neurodegeneration of white matter that resembles frontotemporal dementia beginning in middle
age106. While DAP12 is expressed in a variety of innate immune cells, TREM2 is exclusive to the
myeloid lineage, and within the brain, to microglia. Thus, a microglia-specific defect can drive
early-onset neurodegenerative disease. Impaired clearance of myelin debris was observed in
TREM2-deficient mice fed the demyelinating compound cuprizone, partially reproducing the
pathology in mice50,107. A similar neurodegenerative phenotype also featuring white matter
dysfunction, known as hereditary diffuse leukoencephalopathy, is found in patients carrying rare
heterozygous loss of function mutations in the essential myeloid lineage growth factor receptor
CSF1R108–110, pointing to a common mechanism. Indeed, CSF1R and DAP12 have been reported
to signal via common downstream pathways63. However, one key difference is that at least in
mouse models, TREM2/DAP12 signaling are not essential for microglia survival in young adult
mice and TREM2-deficient brains do not show obvious histological differences, whereas CSF1Rdeficient mice lack microglia and have other brain abnormalities111,112. With TREM2/DAP12
deficiency, functional differences only manifest during disease or aging and are associated with
impaired microglia activation as opposed to resting microglia function. Thus, it is possible that in
Nasu-Hakola disease, a specific loss of DAM leads to the neurodegenerative phenotype.
14

Alzheimer’s disease
Despite these findings, microglia did not feature in mainstream theories of sporadic forms
of neurodegeneration until recently. The past decade has seen a dramatic shift in the estimation of
the immune component of AD, in particular. Large-scale human studies have revealed a multitude
of microglia-enriched loci and pathways linked to AD, and unbiased bioinformatics studies have
implicated the microglia response as the strongest transcriptional signal in AD pathogenesis by
different approaches27. Utilizing human brain transcriptomic data to construct gene interaction
networks revealed changes in immune genes in human AD28 and specifically modules centered on
TREM2113. Epigenetic analysis of a mouse model of AD and human data found widespread
changes in genes regulated by PU.1, a master transcription factor for microglia and other myeloid
cells114. Most of these studies are correlative and performed on whole tissue, so they principally
indicate that microglia proliferate and change during AD, without necessarily allowing causal
inferences to be made.
The first hints of a causal, genetic link between microglia and AD were the identification
of common variants in immune system-specific genes CR1115, CD33116, and INPP5D117 that had
very modest effects on AD risk, on the scale of 5-10% differences in odds ratio. CD33 deficiency
has been studied in a mouse model of AD, showing effects on Aβ that mirror the effects of AD
risk118. These exciting findings lent support to a role for microglia in AD as modifiers of disease
and not just bystanders, but the small effect sizes suggested that microglia were not central players.
Much more revealing from a pathogenetic standpoint was the discovery of a several-fold increase
in AD risk associated with the rare R47H allele of TREM2119,120. This discovery was even more
striking because of the previously known link between TREM2 and Nasu-Hakola disease.
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Subsequent studies of R47H and AD risk confirmed a strong association, although with variable
odds ratios121–126. In addition to R47H, other TREM2 variants have been investigated in relation
to AD risk. The R62H variant occurs relatively frequently in Caucasian populations and
substantially increases AD risk, albeit less than R47H123,124. Among African Americans, the tightly
linked T96K and L211P variants are fairly common and lead to a moderate increase in AD risk of
around 25%127. The R47H variant is extremely rare in the Japanese128 and Han Chinese129
populations; however, the H157Y variant did increase AD risk by several fold in a Han Chinese
cohort, on a similar scale as R47H130.
Other significant risk alleles for AD and other neurodegenerative diseases occur in genes
that are not conventionally thought of as microglia genes but which may nonetheless exert their
effects partially through microglia. The APOE ε4 risk allele, which makes the greatest single-locus
contribution to genetic risk for late-onset AD131,132, appears to boost microglia activation and
worsen pathology in a P301S tauopathy mouse model. At least some of the neurotoxic effects of
ApoE ε4 could be reproduced in vitro with microglia-specific modulation of ApoE isoform. The
authors hypothesized that ApoE ε4 drives microglia activation and the AD risk associated with
ApoE ε4 could be partially through effects on microglia and further downstream, through
neurotoxic astrocytes133. However, they could not definitively demonstrate that this deleterious
effect of ApoE ε4 requires microglia using in vivo microglia-specific manipulations; given the
widespread effects of ApoE on different CNS cell types, an alternative explanation is that the
increased neurodegeneration caused by ApoE ε4 independent of microglia secondarily boosts
microglia activation. Another gene linked to AD risk is clusterin115, or ApoJ, which was recently
shown to be a ligand for TREM2 and may have similar effects as ApoE on microglia.
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Other neurodegenerative diseases
In other neurodegenerative diseases caused by known pathogenic mutations, some
evidence also points to primary microglia involvement. Mutations in SOD1 have long been known
to drive a small subset of familial ALS cases134. Based on the normal function of SOD1 in
generating ROS, which could be neurotoxic, a role for microglia was suspected; however, the
discovery of motoneuron aggregates of mutant SOD1 proteins and a lack of dependence of the
phenotype on endogenous SOD1 made a strong case that the mutant forms cause motoneuronintrinsic cell death135. However, overexpression of mutant SOD1 exclusively in motoneurons136 or
even all neurons137 was not sufficient to drive loss of motoneurons and motor deficits.
Furthermore, deletion of mutant SOD1 from either neurons or microglia could extend lifespan in
mice138, as could transplantation of mutant SOD1 mice with wild-type bone marrow139, suggesting
that the expression of SOD1 in microglia somehow affects disease. Notably, the mechanism for
microglia involvement in this form of ALS may be entirely different from the typical DAM
response; indeed, microglia numbers and morphology appeared to be similar between microgliadeleted and non-microglia-deleted mutant SOD1 mice. A very limited clinical trial of bone marrow
transplantation for sporadic ALS did not have any clinical benefit despite successful engraftment
of some patients140, but sporadic ALS is likely to be fundamentally different from mutant SOD1driven ALS. A recently appreciated driver of familial autosomal dominant ALS and FTD is
intronic repeat expansions in C9orf72. While many studies have now discovered dramatic gainof-function toxic effects of these repeats both from the transcribed RNA as well as from the
unconventionally translated dipeptide repeats141–147, and these effects appear to be sufficient to
cause neurodegeneration, the repeats also lead to decreased C9orf72 expression. A study of
C9orf72-deficient mice found that while there was no overt neurodegeneration due to C9orf72
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deficiency, aged mice had severe immune dysregulation that was traced to macrophage and
microglia function. Without C9orf72, macrophages accumulate lysosomes and have altered
inflammatory responses148. Overall, the clearest sources of pathogenicity with C9orf72 repeat
expansion are neuron-intrinsic, and the effects of C9orf72 deficiency are not seen in heterozygous
mice, which would be analogous to human disease. Still, hampered microglia function might have
a minor contribution for this form of ALS/FTD. Another genetic analysis found that rare loss of
function mutations in TBK1, a gene that is important for interferon production as well as
autophagy, could cause familial ALS/FTD. The clear role of TBK1 in immune function is
interesting, but this study found that several of the implicated mutations impact binding of TBK1
to optineurin but not phosphorylation of targets associated with interferon production149. Thus,
these mutations may affect neuronal pathways independent of microglia or inflammation.
Other neurodegenerative diseases have less clear genetic evidence for microglia
involvement. While an expression quantitative trait locus for MHCII has been linked to a 15-30%
increased risk for sporadic Parkinson’s disease, which suggests that adaptive immunity may have
a role in the disease, other early-onset and sporadic Parkinson’s disease polymorphisms are not
clearly linked to microglia150,151. Huntington’s disease, as with certain familial forms of AD,
ALS/FTD, and Parkinson’s disease, has a clear cause: autosomal dominant repeat expansions in
the huntingtin protein152. These repeats are known to lead to abnormal RNA and protein species
that can interfere with cellular function153. Huntingtin is expressed in various cell types in the brain
and could theoretically act in microglia. While neuron-intrinsic cell death through these
mechanisms is a simple and appealing model for the neuron loss seen in Huntington’s disease, a
few studies have hinted at neuron-extrinsic mechanisms. Peripheral blood from mutant huntingtin
carriers had abnormal inflammatory signatures well before predicted disease onset. Inflammatory
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cytokines, especially IL-6, were elevated in plasma of these premanifest individuals, and their
peripheral blood monocytes produced more cytokines in response to LPS + IFNγ stimulation.
Microglia and macrophages from several mutant huntingtin-expressing mouse models had a
similarly exaggerated inflammatory response154. These findings were strengthened by a later study
using novel cell lines and mouse models. In the BV2 myeloid cell line, in which mutant huntingtin
expression increased expression of the key myeloid lineage factors PU.1 and C/EBP and target
genes IRF1 and TLR2, in addition to IL-6 and TNFα. Direct binding of these transcription factors
to target gene loci was confirmed by chromatin immunoprecipitation, and the upregulation of these
genes was confirmed in primary microglia from mutant huntingtin-expressing mice as well as brain
specimens from Huntington’s disease patients. The most significant finding was that in mice that
conditionally express mutant huntingtin in CX3CR1-positive microglia, expression of these same
genes was elevated. Mutant huntingtin-expressing microglia promoted neuron death in a co-culture
system as well as in their microglia-specific mouse model in vivo in the presence of LPS155.
Therefore, in Huntington’s disease, as in SOD1-linked ALS, expression of the mutant protein in
microglia could be causing microglia dysregulation that causes or contributes to disease.

1.5 Rationale for TREM2 study
The many confounds and ambiguity that arise when interpreting the effect on microglia of
the mutations just described have led to increased attention being paid to the R47H TREM2
variant. Due to specific expression of TREM2 in microglia, the linkage between TREM2 mutation
and disease is mechanistically constrained to microglia-dependent processes. Overall, the most
clearly microglia-related pathogenic mutations in TREM2/DAP12 and CSF1R all seem to reduce
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microglia function while promoting neurodegenerative disease, whereas other pathogenic
mutations may affect microglia but not necessarily in a cell-intrinsic way, making them harder to
interpret. To better understand whether microglia are beneficial or harmful for AD, many
investigators have seized on the TREM2 lead and attempted to answer two essential questions:
what is the effect of TREM2 variants on TREM2, and what is the effect of TREM2 on microglia?
This thesis also broadly adopts this approach. Chapter 2 examines the in vitro and in vivo effects
of AD-associated TREM2 variants and is largely adapted from two studies published as a result of
this work156,157. Chapter 3 examines the mechanism by which TREM2 acts in microglia, and is
derived partially from an additional study published as a result of this work158. As TREM2 variants
modify AD risk in heterozygosity and gene dose-dependent effects are also observed in mouse
models, regulation of TREM2 expression likely plays an important role in disease progression.
Thus, Chapter 4 will describe an unbiased screen for genes that regulate TREM2 surface levels. A
better understanding of the basic biology of TREM2 regulation, function in microglia, and effect
of mutations will pave the road for future therapeutic efforts. This introductory chapter (Chapter
1) was derived in part from a review written as part of this thesis159.
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Chapter 2: Impact of TREM2 variants on
TREM2 function in vitro and in vivo
Given the strong, consistent association of R47H with increased AD risk, and the
identification of additional variants with weaker associations with AD, whether and how these
variants affect TREM2 function is of utmost importance to understand and target TREM2 in AD.
If risk is associated with loss of function, this would favor TREM2-enhancing therapies, whereas
if risk is associated with gain of function, this would favor TREM2-inhibiting therapies.
Correlating genetic risk with functional impact in vitro can help to address this question, an
approach taken in the first part of this chapter. Regarding the best-established R47H variant, in
vitro experiments and study of cross-sectional human specimens have suggested the R47H
variant decreases TREM2 function, but both approaches have caveats. In vitro studies may not
pinpoint a physiologically relevant readout. On the other hand, AD cases partially driven by
microglia dysfunction may have a different natural history than other sporadic cases,
complicating cross-sectional analysis. A mouse model of AD can strictly control timing and
genetic background to isolate the effect of the variant. In addition, the human and mouse genes
only share about 77% sequence identity, meaning that non-conserved regions could potentially
modulate the repertoire of ligands, overall binding affinity, and the effects of variants. To
address both issues, we generated two mouse lines with either common variant (CV) or R47H
human TREM2 (hTREM2) in place of murine TREM2 (mTREM2) in the 5XFAD AD mouse
model to investigate the effect of the R47H variant in a controlled in vivo setting.
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2.1 In vitro characterization of TREM2 variants
We generated a retroviral construct overexpressing human TREM2 and human DAP12
under control of the CMV promotor and separated by an internal ribosomal entry sequence
(IRES). This construct was used to generate the corresponding point mutations by site-directed
mutagenesis. Once the panel of constructs was obtained, we packaged retroviral particles by
transfecting 293T cells with equal amounts of construct DNA and harvesting viral particles in
parallel. To assay TREM2 signaling, we started with the 2B4 NFAT-GFP cell line, which is a T
cell hybridoma that expresses EGFP in response to calcium signaling. After transducing
TREM2/DAP12 into these cells, we sorted transduced cells by two rounds of fluorescenceactivated cell sorting (FACS) for TREM2 expression to select stable expressers. The common
variant of TREM2 (TREM2-CV) and non-transduced reporter cells served as positive and
negative controls, respectively. By flow cytometry, surface expression ranged from about 50% to
120% of TREM2-CV (Fig. 1A). The T66M variant had no detectable surface expression, as
previously shown, and did not show any activation in our assay (data not shown). On the other
hand, the R52H, R62C, and T96K mutations demonstrated somewhat lower surface expression
despite their higher RNA expression, which may reflect a true defect in protein trafficking or
simply technical variation. Using these reporter lines, we analyzed TREM2 activation in
response to a variety of known lipid ligands. Each ligand was coated on a 96–well plate at
different concentrations, and reporter cells containing each TREM2 variant were subsequently
plated in duplicate. After 12 hours, the percentage of GFP+ cells at each concentration was
determined by flow cytometry. Then, the baseline activation with no ligand was subtracted from
each respective activation curve and area under the curve (AUC) relative to TREM2-CV was
used to compare overall activation. An example of a full activation curve is shown in Fig. 1B.
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Because of the correlation between surface expression and activation seen with antibody
stimulation, we used the activation/expression ratio to determine functional impact. Fig. 1C
shows activation versus surface expression plots for the purified lipid ligands phosphatidylserine
(PS), sulfatide (Sulf), and phosphatidylcholine (PC). As lipoproteins contain a variety of
phospholipids, we tested whether abundant serum lipoproteins such as high density lipoprotein
(HDL) and low-density lipoprotein (LDL) could activate TREM2 in our reporter system. Indeed,
both HDL and LDL activated TREM2 variants in a similar pattern as seen for purified
phospholipids (Fig. 1D). These results extend the range of TREM2 ligands and are consistent
with the recent observation that lipoprotein particles containing the apolipoprotein E (ApoE) also
bind TREM261,62, which is notable given the association of ApoE polymorphisms with AD.
As previously shown40, the R47H polymorphism has a profound negative impact on
signaling in response to all tested ligands except PC, which in turn elicited a normal response
from all variants. The R62C polymorphism showed a similarly dramatic reduction in activation.
The H157Y and R62H variants demonstrated a lesser defect. To the contrary, T96K and D87N
had consistently higher activation. R52H, R136W, L211P, and E151K were neutral overall. The
percentage deviations of each variant from TREM2-CV across ligands are summarized in Fig.
1E. As Q33X leads to truncation of nearly the entire protein, it presumably leads to complete
loss of function and thus was not assayed.
To correlate these variants to human genetics, we analyzed data on these variants in the
NIMH AD Genetics Initiative Study and AD Sequencing Project (Table 1). Family-based
association analysis (FBAT) in the NIMH AD families yielded a p-value of 0.004 for R47H,
consistent with our previous report in the same NIMH families (11) and confirmed in ADSP
(p<3.45e-12; OR=4.5). Other rare variants in TREM2 were not present in more than ten
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statistically informative families, thereby preventing the computation of reliable p-values.
However, several variants were frequent enough to be suggestive between both datasets. R62H
had an odds ratio (OR) of 1.7 in NIMH families, confirmed in ADSP (p=0.006; OR=1.4). The
related R62C was found in two affected individuals from one NIMH family and had an OR of
0.58 in ADSP, but numbers were too small to draw conclusions. T96K and L211P, which were
almost completely linked in both datasets, had OR around 10 in NIMH families, but this was not
supported by the replication sample (p=0.85; OR=1.04; p=0.59; OR=1.13, respectively). On the
other hand, D87N had an OR of 0.89 in NIMH families but was significantly associated with risk
in ADSP (p=0.017; OR=2.3). Both of these variants showed conflicted results in other cohorts,
so their contribution to AD risk is still questionable. The stop gain Q33X was biased toward
affected individuals in NIMH families and statistically significant for increased risk in ADSP
(p=0.025). Finally, H157Y was found in 5/8 affected individuals, but no unaffected individuals
were available for comparison; however, it significantly increased risk in ADSP (p=0.01;
OR=4.7), and additional studies have replicated this risk. Overall, in addition to R47H, which
already had strong evidence for increased AD risk and decreased in vitro function, we provide
evidence that R62H, H157Y, and Q33X also show this same correlation. On the other hand,
D87N and T96K/L211P showed dramatic gain-of-function effects in our assay but the genetics is
not established conclusively.

2.2 In vivo characterization of R47H variant
To understand the in vivo properties of hTREM2 and the R47H polymorphism, we
generated several BAC transgenic lines expressing either the common hTREM2 variant (CV) or
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the R47H polymorphism (R47H). A BAC clone was selected that contained abundant flanking
sequence of the TREM2 gene to allow endogenous expression of TREM2. We first assessed cell
surface expression of hTREM2 in each of these lines to ensure that both CV and R47H
transgenic mice generated using this strategy express hTREM2 on the cell surface in a pattern
paralleling that of murine TREM2, i.e. on myeloid cell populations previously shown to express
TREM2. We selected two lines - one carrying CV and one carrying R47H - that expressed
similar levels of hTREM2 on the cell surface. Thioglycolate-elicited peritoneal macrophages
were collected on day 3 post-injection and stained for hTREM2, revealing expression of both
transgenes at similar levels in these lines (Fig. 2A). Bone marrow-derived macrophages
(BMDMs) were stained for hTREM2 after 2 days of culture, showing hTREM2 specifically on
F4/80+ differentiated cells, again at similar levels in both transgenic lines (Fig. 2B). hTREM2
mRNA in the cortex was quantified by qPCR, revealing slightly lower mRNA in R47H
compared to CV brains (Fig. 2C). However, quantification of hTREM2 protein in the brain by
immunoblotting the PBS-insoluble fraction of hippocampal homogenates (including membranebound protein) showed similar levels between transgenic lines on the protein level (Fig. 2D).
These mice were bred with mTREM2–/– (KO) mice to obtain CV and R47H transgenic mice
lacking endogenous TREM2. Next, we crossed CV and R47H to 5XFAD mice, in which
amyloid pathology is driven by overexpression of mutant human APP and PS1, and compared
these CV+ mTREM2-/- 5XFAD (CV-KO-5xFAD) and R47H+ mTREM2-/- 5XFAD (R47H-KO5XFAD) mice to mTREM2-/- 5XFAD (KO-5XFAD) mice at 8 months of age. hTREM2 was
visualized by immunofluorescence microscopy in steady-state microglia but not in other CNS
cells (Fig. 2E). Quantification of staining intensity showed that microglia had similar hTREM2
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levels between transgenic lines on a per-voxel basis, and staining intensity increased in 5XFAD
brains (Fig. 2F).
To understand the effect of CV and R47H on microglia, we started by examining
microglial numbers throughout the cortex and hippocampus (Fig. 3A), as well as specifically
adjacent to plaques (Fig. 3B). By both measures, microglial numbers were enhanced by both CV
and R47H transgenes compared to KO, with CV having a larger effect. Since microglia
clustering around plaques has been proposed to promote A

clearance, we also measured Aβ

levels by both imaging and ELISA. Total fibrillar plaque area in the cortex, subiculum, and
hippocampus (excluding subiculum) was determined by manual selection of the relevant regions
followed by automated determination of threshold and calculation of percent area covered (Fig.
4A). As a complementary measurement, flash-frozen cortical tissue was homogenized
sequentially in PBS and guanidine solutions to obtain PBS-soluble and -insoluble fractions. Aβ140

and Aβ1-42 levels were measured in both fractions by ELISA in the hippocampus (Fig. 4B) and

cortex (Fig. 4C). By either modality, Aβ was generally unaltered by CV and R47H, excepting a
slightly decrease in hippocampal PBS-soluble Aβ species. Thus, while R47H affects
microgliosis, the decreased number of microglia in R47H-KO-5XFAD compared to CV-KO5XFAD was not sufficient to affect plaque coverage, or to cause a detectable difference in
accumulation of Aβ plaques in our model.
To more clearly understand the microglia-intrinsic effect of the R47H variant, we
performed qRT-PCR analysis of whole cortex for microglia activation-related transcripts. The
microglia-specific genes Spp1, Gpnmb, and Cst7, encoding osteopontin, osteoactivin, and
cystatin F, respectively, are among the most upregulated in AD models39,40. All three activation
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markers were much more upregulated in CV-KO-5XFAD than in other genotypes, suggesting
that the R47H variants exhibit a defect in promoting microglia activation (Fig. 5A).
To acquire a global snapshot of transcriptional differences between microglia in different
conditions, we performed microarray analysis of sorted microglia from brains of 8.5-month-old
5XFAD animals. A gene list of microglial activation markers was compiled from our previous
data using the same platform by selecting genes upregulated at least 2-fold between 5XFAD and
non-5XFAD microglia and ordering them based on their upregulation in TREM2-deficient
microglia. Genes that were more highly upregulated in TREM2-sufficient compared to TREM2deficient microglia were deemed TREM2-dependent, and genes with similar upregulation were
deemed TREM2-independent. Unsupervised clustering of samples based on this microglia
activation signature grouped KO-5XFAD and R47H-KO-5XFAD together, distinct from CVKO-5XFAD, and revealed a stepwise increase in activation from KO-5XFAD to R47H-KO5XFAD to CV-KO-5XFAD (Fig. 5B). Furthermore, differences between the groups were more
pronounced among TREM2-dependent than TREM2-independent genes. We verified that Spp1
was upregulated on the protein level in a TREM2-dependent manner by confocal microscopy
(Fig. 5C). A large proportion of CV-KO-5XFAD microglia in cortex and hippocampus were
positive for Spp1 staining, whereas few positive microglia were observed in R47H-KO-5XFAD
and virtually none in KO-5XFAD (Fig. 5D). We conclude that CV mediates activation of
microglia, which is partially affected by R47H, and Spp1 is a sensitive marker of TREM2dependent activation on the mRNA and protein level.
Given recent studies on TREM2 polarization during Aβ accumulation, we sought to shed
light on localization of CV and R47H hTREM2. While hTREM2 is exclusively detected in Iba1+ microglia using an antibody directed against its intracellular C-terminus (Fig. 2), brain
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sections stained with an antibody against hTREM2 extracellular domain (ECD) showed diffuse
distribution of hTREM2 outside of Iba-1+ voxels (Fig. 6A) and hTREM2 C-terminus+ voxels in
CV-KO-5XFAD mice (Fig. 6B), suggesting the presence of soluble TREM2. The intensity of
hTREM2 ECD staining was quantified both within Iba-1+ voxels and within Iba-1- voxels in the
cortex (Fig. 6C) and hippocampus (Fig. 6D). While hTREM2 ECD intensity within microglia
remained relatively constant between non-5XFAD and 5XFAD images, hTREM2 intensity
outside microglia dramatically increased in CV-KO-5XFAD images and slightly increased in
R47H-KO-5XFAD images. This non-microglial staining was absent in KO-5XFAD.
A particularly intense hTREM2 ECD staining was observed on a fraction of nonmicroglial cells and Aβ plaques. Co-staining for NeuN and hTREM2 ECD demonstrated that the
hTREM2 ECD+ cells are neurons (Fig. 6E). Quantification of hTREM2 intensity specifically in
NeuN+ neuronal soma showed that CV-KO-5XFAD mice had higher frequency of hTREM2+
neurons (Fig. 6F) and higher hTREM2 intensity in neuronal soma (Fig. 6G) than R47H-KO5XFAD mice in both cortex and hippocampus. Similarly, hTREM2 intensity in Aβ plaques was
higher in CV-KO-5XFAD mice than R47H-KO-5XFAD mice in both cortex and hippocampus
(Fig. 6H). While TREM2 has been reported to bind damage-associated phospholipids such as
phosphatidylserine, hTREM2 ECD did not colocalize to APP+ dystrophic neurites (Fig. 6I), and
nuclei of hTREM2+ neurons did not show morphological abnormalities such as pyknosis or
fragmentation (Fig. 6J). To verify that the unique distribution of hTREM2 ECD reflected soluble
TREM2, we performed immunoblots on the PBS-soluble fraction of hippocampal tissue
homogenates for TREM2 (Fig. 6K). A low molecular weight hTREM2 smear was detected, with
the lower range of the smear corresponding to the predicted soluble hTREM2 size of 20 kDa.
Densitometry confirmed higher soluble TREM2 levels in CV-KO-5XFAD compared to R47H28

KO-5XFAD. Overall our results show for the first time that soluble TREM2 production
markedly increases during Aβ accumulation in a mouse model and associates directly with
neurons and plaques in vivo. The increase of soluble TREM2 and its broad distribution are both
impaired by the R47H variant.
We sought to shed light on the differences in soluble TREM2 observed between
genotypes. To that end, we generated RAW264.7 macrophage-like cell lines that overexpress
either CV or R47H. Previous work had indicated that diverse immunostimulatory molecules such
as LPS, TNFα, and IFNγ could lead to downregulation of cell-surface TREM2. We found that in
our system, surface expression of both CV and R47H, as measured by flow cytometry, could
indeed be downregulated by these molecules within two hours of stimulation (Fig. 7A). While
LPS and TNFα led to a rapid down-regulation of surface hTREM2 at 30 minutes and partial
recovery by 2 hours, IFNγ had no detectable effect at 30 minutes but decreased surface hTREM2
by 2 hours. To determine whether these changes were due to cleavage, we lentivirally transduced
cells with Cas9 and a guide RNA against Adam17, which was previously shown to cleave
TREM2. Unlike non-transduced cells, a fraction of transduced cells retained TREM2 surface
expression upon LPS treatment (Fig. 7B); this seemingly cleavage-resistant fraction (+) was
purified from the remainder of cleavage-sensitive transduced cells (-) by fluorescence-activated
cell sorting and both populations were analyzed by immunoblot for Adam17 protein levels (Fig.
7C). The (-) population showed only a slight decrease in Adam17 protein relative to nontransduced cells, possibly reflecting the presence of heterozygous Adam17 knockout, whereas
the (+) population showed virtually no residual Adam17 expression and were considered
Adam17 KO. LPS, TNFα, and IFNγ treatment all failed to decrease TREM2 surface expression
in CV-Adam17 KO and R47H-Adam17 KO (Fig. 7D). These results suggest that various
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myeloid cell signaling pathways that may be activated in neuropathology can induce Adam17dependent release of soluble TREM2 and that R47H polymorphism does not directly impact this
process.
Our study provides conclusive evidence that the R47H polymorphism reduces TREM2dependent phenotypes in microglia in vivo, in the setting of endogenous ligands of TREM2 in the
mouse brain. Compared to CV-expressing brains, R47H-expressing brains had decreased
microglia numbers, slightly increased soluble Aβ, and dramatic reductions in activation markers
and soluble TREM2. We further suggest that soluble TREM2 differences between the two lines
are due to differences in microglial activation rather than intrinsic differences in cleavability
between CV and R47H TREM2. Future studies should examine some of the other established
TREM2 variants, such as R62H or H157Y, in vivo. More importantly, better powered genetic
data on rare TREM2 variants such as D87N and T96K/L211P, along with additional functional
studies, will help to clarify whether TREM2 gain-of-function is detrimental in AD.
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Figure 1. TREM2 variants affect ligand binding in a reporter cell assay.
A panel of TREM2 variant-expressing reporter cells were generated by retroviral TREM2
overexpression and sorted for TREM2 surface expression. (A) TREM2 gMFI of different
variants compared to common variant (CV). (B) Activation of different reporter lines in response
to different concentrations of plate-coated phosphatidylserine. (C) Activation AUC vs. surface
expression of different variants in response to phosphatidylserine, sulfatides, and
phosphatidylcholine. Black line represents a relative activation/surface expression ratio of 1
compared to CV. Red points are significantly higher than CV, while blue points are significantly
lower. (D) Similar plots as (C) for plate-coated HDL and LDL. (E) Summary of variants for
different ligands compared to CV.
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Table 1. TREM2 gene variants found in the NIMH family-based WGS data and tested for
replication in the ADSP case-control samples.
Codon

#Fam-

#Aff

Med.

#Unaff

Med.

MAF

change

ilies

Carr

AAO

Carr

Age

R62C

1

2/2

78

0/0

--

0.00068

Q33*

2

4/4

71

1/3

73

R47H

20

35/53

72.5

2/14

T96K

9

11/16

71

R62H

11

12/23

H157Y

4

L211P
D87N

OR

NIMH

ADSP-WES P-val; OR(CI);

(P-val)

MAF

NA

--

0.65; 0.58(0.05~6.43); 0.0001

0.00170

NA

--

0.025; (NA); 0.0001

72

0.01390

11.7

0.004

3.45E-12; 4.5(2.7~7.4); 0.005

1/6

79

0.00475

11

--

0.85; 1.04(0.65~1.67); 0.003

73

7/18

72

0.00746

1.7

--

0.006; 1.44(1.1~1.88); 0.01

5/8

74

0/0

--

0.00203

NA

--

0.01; 4.7(1.04~21.33); 0.0006

10

12/18

71

1/6

79

0.00509

10

--

0.59; 1.13(0.71~1.81); 0.003

5

4/13

76

2/6

76

0.002

0.89

--

0.017; 2.3(1.1~5.1); 0.0015

#Aff Carr: affected carriers over total affected subjects. Med. AAO: median age of onset in
affected carriers. #Unaff Carr: unaffected carriers over total unaffected subjects. Med. Age:
median of last known ages of the unaffected carriers. MAF: minor allele frequency. CI:
confidence interval.
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Figure 2. CV and R47H transgenes are specifically expressed in myeloid cell populations at
comparable levels.
(A) Thioglycolate-elicited peritoneal macrophages were stained for macrophage marker F4/80
and hTREM2, showing similar level of hTREM2 in F4/80+ cells from both CV and R47H mice.
(B) Bone marrow-derived macrophages were stained after 2 days in culture and gated on
CD11b+ cells. (C) hTREM2 mRNA expression in KO, CV-KO and R47H-KO whole cortical
tissue. (D) Immunoblot of hTREM2 and actin in the PBS-insoluble fraction of hippocampal
tissue homogenates. (E) Confocal microscopy of cortex of CV-KO, R47H-KO, or KO 5XFAD
or non-5XFAD mice shows colocalization of hTREM2 C-terminus (green) and microglial
marker Iba-1 (red); methoxy-X04 staining for plaques is shown in blue. (F) Quantification of
staining intensity of hTREM2 in the cortex and hippocampus. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 by one-way ANOVA with Holm-Sidak multiple comparisons testing.
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Figure 3. R47H exhibits reduced microglia numbers relative to CV.
(A) Representative images and quantification of Iba-1+ pixels. (B) Representative images of
plaque-associated microglia and quantification of microglial density in a 15 or 30 μm shell
around the plaque.
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Figure 4. CV and R47H transgenes do not affect Aβ accumulation in the cortex or hippocampus.
(A) Quantification of plaques by fluorescence microscopy of methoxy-X04 fibrillar plaques.
(B,C) Quantification of Aβ1-40 and Aβ1-42 species in PBS-soluble and guanidine-soluble
fractions of hippocampal (B) or cortical (C) homogenates.
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Figure 5. CV-KO-5XFAD mice have increased microglia activation compared to R47H-KO5XFAD and KO-5XFAD mice.
(A) Quantitative RT-PCR on whole cortical tissue for neurodegeneration-associated microglial
activation markers Cst7, Spp1, and Gpnmb, as well as classical inflammatory cytokines Tnf, Il6,
and Il1b, showing dramatically higher microglial activation markers but not inflammatory
cytokine transcripts in CV-KO-5XFAD compared to other groups. (B) Microarray analysis of
activation markers in sorted microglia shows that KO-5XFAD and R47H-KO-5XFAD cluster
together and separately from CV-KO-5XFAD. (C) Spp1 protein is detected by confocal
microscopy in CV-KO-5XFAD brains and largely absent from R47H-KO-5XFAD, KO-5XFAD,
and non-5XFAD brains. (D) The percent of Iba-1+ (microglia) pixels that were also Spp1+ was
quantified in cortex and hippocampus. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by oneway ANOVA with Holm-Sidak multiple comparisons testing.

36

37

Figure 6. CV-KO-5XFAD shows unique localization of soluble hTREM2 to neurons, plaques,
and other non-microglial spaces.
(A) Representative confocal images showing plaques (methoxy-X04, blue), microglia (Iba-1,
red), and hTREM2 extracellular domain (ECD) (green) in the cortex. (B) Representative
confocal images showing plaques (blue), hTREM2 C-terminus (red), and hTREM2 ECD (green).
In CV-KO-5XFAD brains, hTREM2 ECD is present in voxels that lack either Iba-1 or hTREM2
C-terminus staining, whereas in R47H-KO-5XFAD, hTREM2 ECD largely colocalizes with Iba1 and hTREM2 C-terminus. (C, D) Mean intensity of hTREM2 ECD staining was quantified in
Iba-1-positive (microglial) voxels and Iba-1-negative (non-microglial) voxels in (C) cortex and
(D) hippocampus, showing similar expression levels in microglia but a significant increase
outside of microglia in CV-KO-5XFAD brains only. (E) Representative confocal images
showing plaques (methoxy-X04, blue), neuronal soma (NeuN, orange), and hTREM2 (green).
(F) Frequency of hTREM2+ neurons and (G) mean hTREM2 intensity in neuronal soma was
quantified in cortex and hippocampus. (H) Mean intensity of hTREM2 staining was quantified in
methoxy-X04+ plaques in cortex and hippocampus. hTREM2 ECD staining on plaques and
neuronal soma was significantly higher in CV-KO-5XFAD compared to R47H-KO-5XFAD. (I)
Representative confocal image of plaques (blue), APP+ dystrophic neurites (red), and hTREM2
ECD (green), showing a relative lack of soluble TREM2 on dystrophic neurites. (J)
Representative confocal slice showing nuclei (ToPro-3, red) and hTREM2 ECD (green) within
NeuN+ neuronal soma. hTREM2+ neurons do not show nuclear abnormalities characteristic of
apoptosis. (K) Immunoblot of PBS-soluble fraction of hippocampal homogenates for hTREM2,
showing a hTREM2 smear at lower molecular weight than full-length hTREM2, indicating
soluble TREM2. Densitometric analysis normalized to actin was performed, showing that CVKO-5XFAD mice had more soluble TREM2 than CV-KO and R47H-KO-5XFAD mice.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA with Holm-Sidak multiple
comparisons testing.
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Figure 7. Various immunostimulatory signals induce similar CV and R47H hTREM2 cleavage
from the cell surface.
(A) Representative flow cytometry plots demonstrating that both CV and R47H hTREM2 are
lost from the cell surface of RAW264.7 upon treatment with LPS, TNFα, or IFNγ (untreated,
gray shaded; 30 min., blue dashed line; 2 hr., red solid line). (B) Quantification of gMFI of LPS,
TNFα, and IFNγ treated cells relative to untreated cells. Shown is mean ± SEM for three
independent experiments. (C) Adam17 was knocked out in CV- and R47H-expressing
RAW264.7 cells. Non-transduced cells (ctrl; gray shaded) uniformly lost hTREM2 surface
expression. Transduced cells (solid red line) had two populations, one that retained hTREM2
surface expression (+) and one that lost hTREM2 surface expression (-), and these two
populations were sorted by FACS. (D) Immunoblot for Adam17. (E) Experiments conducted as
in (a, b) using Adam17 KO. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way
ANOVA with Holm-Sidak multiple comparisons testing.
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Chapter 3: TREM2-dependent pathways in
activated microglia
A key outstanding question is how TREM2 facilitates microglial activation. While
TREM2-deficient mice show defects in proliferation, survival, and plaque localization, the
mechanistic basis for these defects is unknown. Understanding the mechanism of TREM2
function would shed light on potential therapeutic options targeting microglia in AD.
Furthermore, the microglial response to neuropathology has often been viewed from the lens of
M1 vs. M2 polarization, but the value of this paradigm for neurodegenerative disease has been
challenged by recent studies of microglia acutely isolated from various models of
neurodegeneration that suggest a common neurodegeneration-associated activation signature
distinct from M1 or M2. As part of this activation signature, the most highly upregulated
transcription factor is Bhlhe40, which is known to promote inflammatory responses in
experimental autoimmune encephalitis. Most of this signature, including Bhlhe40, is ablated in
TREM2-deficient animals in both the 5xFAD amyloid plaque model and the cuprizone-induced
demyelination model. Thus, Bhlhe40 is a candidate on-switch that may contribute to microglial
activation downstream of TREM2.
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3.1 The role of TREM2 in microglia energy metabolism
To understand the mechanism by which TREM2 facilitates microglial activation in
neurodegenerative states, we have expanded upon our recent findings that Dap12- or TREM2deficient primary microglia and BMDMs show greater susceptibility to CSF-1 withdrawal.
Previous studies had indicated that TREM2 can activate MAPK and calcium signaling; however,
given the significant effect of growth factor signaling on the PI3K-Akt-mTOR pathway, we
chose to quantify the effect of TREM2 deficiency on this pathway by Western blot. After
culturing WT and TREM2-deficient BMDMs in standard or low CSF-1 conditions, we noted that
CSF-1-deprived TREM2-deficient BMDMs showed a dramatic reduction in both mTORC1 and
mTORC2 signaling, as measured by S6K phosphorylation, 4EBP phosphorylation, Akt S473
phosphorylation, and NDRG1 phosphorylation (Fig. 8A). Interestingly, CSF-1 deprived WT
BMDMs showed a modest and variable reduction in these signaling events, suggesting to us that
in this time frame, WT BMDMs could compensate for decreased CSF1R signaling through
TREM2. To test this hypothesis, we cultured TREM2 reporter cells (as described in Aim 1.1)
under normal culture conditions or with serum starvation to mimic CSF-1 deprivation. While
reporter cells had a low level of activation under normal culture conditions, they robustly
activated under starvation conditions, and this activation could be blocked by adding antiTREM2 antibody (Fig. 8B). From these data, we conclude that TREM2 activity may increase
during stressful conditions to compensate for decreases in mTOR signaling.
Given the essential role of mTOR in coordinating cellular metabolism and energy state,
we decided to examine key cellular functions regulated by mTOR, namely autophagy and ATP
production. We utilized the same experimental setup as before, using WT and TREM2-deficient
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BMDMs cultured with standard or low CSF-1 overnight. Using the Seahorse analyzer, we
measured baseline and glycolytic flux and oxidative phosphorylation at baseline and with stimuli
that elicit maximum activity. Concordant with the exaggerated decrease in mTOR activity in
CSF-1-deprived TREM2-deficient cells, baseline and maximal flux were relatively similar
between WT and TREM2-deficient cells cultured in standard CSF-1 concentration, but TREM2deficient cells progressively dropped below WT cells as CSF-1 concentration was lowered (Fig.
8C). ATP concentrations in cells cultured this way showed a similar pattern, with CSF-1deprived TREM2-deficient having dramatically less ATP (Fig. 8D). Next, we measured
autophagic flux in these cells by comparing the LC3-II/LC3-I ratio with or without the addition
of bafilomycin, an inhibitor of lysosomal acidification. We found that indeed, LC3-II/LC3-I ratio
was greatly increased specifically in CSF-1-deprived TREM2-deficient cells (Fig. 8E).
Furthermore, when these cells were pelleted and examined by transmission electron microscopy,
we noticed an accumulation of multilamellar vesicles consistent with autophagosomes (Fig. 8F).
These findings show that TREM2-deficient cells are more susceptible to stress-induced lowenergy state.
To elucidate the in vivo significance of these findings, we isolated microglia from WT
and TREM2-deficient mice that were either on the 5XFAD mouse model or littermate controls.
We performed Western blot and TEM analysis as described for BMDMs. Surprisingly, we found
that microglia from non-5XFAD WT and TREM2-deficient mice, as well as from 5XFAD WT
mice, had similar levels of phosphorylation of mTORC1 and mTORC2 target proteins, as well as
similar LC3-II/LC3-I ratio, whereas 5XFAD TREM2-deficient microglia had dramatically
reduced mTOR activity and increased LC3-II/LC3-I ratio (Fig. 9A). In addition, 5XFAD
TREM2-deficient microglia had large numbers of multilamellar vesicles by TEM (Fig. 9B).
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These results mirror our in vitro results with Aβ deposition substituting for CSF-1 deprivation,
and strongly suggest that microglia exposed to amyloid pathology experience stress conditions
that mimic CSF-1 deprivation in terms of mTOR suppression and induction of autophagy.
Previously, it had been thought that TREM2-deficient microglia simply do not respond to Aβ
pathology and resemble homeostatic microglia; however, our findings indicate that signaling
pathways in Aβ-exposed TREM2-deficient microglia are dramatically altered compared to
steady state. More generally, neurodegenerative disease appears to release cytotoxic signals that
are normally counterbalanced by increased TREM2 signaling and reinforcement of the mTOR
pathway.
To determine whether these in vivo defects are responsible for the reported phenotypes of
TREM2-deficient mice in the 5XFAD model, we sought to restore mTOR signaling by
stimulating pathways that bypass TREM2. We turned to our in vitro model of CSF-1-deprivation
of BMDMs, in which we tried adding several candidate compounds into the culture during CSF1 deprivation, using viability and metabolic measures as readouts of rescue. Many pattern
recognition receptors initiate signaling cascades linked to mTOR. We found that addition of TLR
agonists such as LPS, PAM3CSK4, and CpG could entirely rescue viability with CSF-1
deprivation in both WT and TREM2-deficient BMDMs (Fig. 10A). This was also true for TLR
agonist-depleted zymosan, which activates Dectin-1 (Fig. 10B). Thus, alternative activating
receptors could compensate for TREM2 in vitro. We also tested whether directly modulating
metabolic parameters, even further downstream, could provide benefit in this system. Adding the
creatine analog cyclocreatine led to a striking increase in viability in both WT and TREM2deficient cells (Fig. 10C). Interestingly, while zymosan promoted ATP generation in cells,
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cyclocreatine appeared rather to stabilize levels, significantly reducing ATP level in all groups
except CSF-1-deprived TREM2-deficient cells, where it increased ATP level (Fig. 10D).
Because of previously reports utilizing cyclocreatine treatment in the brain, and the likely
dramatic off-target effects of using TLR agonists in vivo, we administered cyclocreatine to WT
and TREM2-deficient 5XFAD mice from the beginning of plaque formation at 2 months to the
previously examined timepoint of 8 months as a microglial rescue experiment. Immunoblotting
of sorted microglia from these groups showed that cyclocreatine-fed TREM2-/-5XFAD mice had
restored mTORC1 and mTORC2 activity and decreased autophagic flux by LC3II/LC3I ratio
(Fig. 11A). In addition, microglia clustering around plaques was partially restored (Fig. 11B), as
well as expression of the microglial activation marker Spp1 (Fig. 11C). Overall, these results
demonstrate that TREM2 signaling impacts mTOR signaling and global microglia metabolism
and downstream metabolic compensation can rescue the TREM2 phenotype. These findings
provide a unifying mechanism for the diverse microglial functions affected by TREM2
deficiency. Importantly, cyclocreatine did not boost mTOR activity or Spp1 expression by itself
but only in the TREM2-/-5XFAD background, hinting that TREM2 downstream pathways are
necessary but not sufficient to activate microglia.

3.2 Role of Bhlhe40 upregulation in microglial activation
We and others have previously defined a transcriptomic signature characteristic of
microglial activation, part of which is dependent on TREM2. Among these genes, the most
highly upregulated transcription factor, in multiple datasets, is Bhlhe40. In particular, Bhlhe40 is
strongly upregulated in the 5XFAD model compared to other genes (Table 2). This gene has
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been linked to pro-inflammatory responses in other immune cells160 and is not expressed in
steady-state microglia, suggesting that it could be an on-switch that controls part of the activation
signature.
First, we attempted to directly visualize the pattern of Bhlhe40 expression by crossing
Bhlhe40-EGFP mice to 5XFAD mice. Unfortunately, we found by confocal microscopy that
while other cells such as some neurons and astrocytes express EGFP at detectable levels at
steady state and in the 5XFAD model, microglia do not, even surrounding plaques (Fig. 12).
These results suggest that while Bhlhe40 may be upregulated during disease, the final expression
level is still far less than other cells that express Bhlhe40. Even so, Bhlhe40 could be controlling
some microglial activation genes. Therefore, we bred Bhlhe40-deficient mice to 5XFAD mice
and analyzed mice with abundant pathology, around 9 months old.
The most direct measure of Bhlhe40 function, given that Bhlhe40 is a transcription
factor, would be to analyze transcriptional changes in microglia during disease. Therefore, we
sorted microglia from Bhlhe40+/+ and Bhlhe40-/- 5XFAD brains and performed microarray
analysis. In accordance with the low expression seen in Bhlhe40-EGFP microglia, few
significant differences were detected between the two genotypes (Fig. 13A), and genes that were
altered did not have any obvious relationship or large fold changes. Examination of microglial
genes known to be altered in the 5XFAD model showed that activation genes such Spp1,
Gpnmb, and Cst7 were indeed expressed in all samples, but equally between genotypes (Fig.
13B). Interestingly, microglia clustering around plaques was more pronounced in the Bhlhe40-/mice. (Fig. 14A). Furthermore, astrocyte clustering around plaques, which is affected by
microglial clustering, was also increased, but not significantly (Fig. 14B). Thus, we conclude
that Bhlhe40 is not expressed highly in microglia and is dispensable for the microglia response to
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Aβ plaques, but it may serve to dampen inflammatory responses through effects in other cell
types. Based on lists of genes upregulated in activated microglia, there do not seem to be other
transcription factors that “switch on” during disease, suggesting that perhaps the transcriptional
program of activated microglia is mediated instead by post-translational effects or
downregulation of transcription factors.

46

Figure 8. TREM2-deficient BMDMs show increased sensitivity of mTOR-dependent cell
functions to growth factor deprivation.
(A) CSF-1 deprived (0.5% L-cell conditioned medium) TREM2-deficient BMDMs have
significantly lower mTORC1 and mTORC2 activity as measured by Akt, NDRG1, S6K, and
4EBP1 phosphorylation. (B) Serum-starved TREM2 reporter cells increase activation of TREM2
relative to 10% serum conditions. (C) ECAR is lower in TREM2-deficient BMDMs compared to
WT BMDMs and becomes progressively lower with decreasing CSF-1 concentration. (D) ATP
levels are dramatically decreased in CSF-1 deprived TREM2-deficient BMDMs. (E) LC3II/LC3-I increases dramatically in CSF-1 deprived TREM2-deficient BMDMs and reflects
increased autophagic flux as shown by addition of bafilomycin. (F) TEM images of BMDMs
reveals presence of multilamellar vesicles in TREM2-deficient BMDMs, characteristic of
autophagosomes. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA with
Holm-Sidak multiple comparisons testing.
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Figure 9. TREM2-deficient microglia exhibit suppressed mTOR activity and increased
autophagy in vivo in the 5xFAD model.
(A) Western blot of sorted microglia from WT or TREM2-deficient mice with or without the
5xFAD transgene shows similar phosphorylation of mTOR effector genes in all groups except
TREM2-deficient 5xFAD, which has much lower activity. On the other hand, LC3-II/LC3-1
ratio is greatly increased in this group. (B) TEM of pelleted sorted microglia from these groups.
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Figure 10. Alternative pathways can compensate for sensitivity to CSF-1 deprivation associated
with TREM2 deficiency.
(A) TLR agonists, (B) cyclocreatine, and (C) depleted zymosan can fully restore viability in
CSF-1 deprived WT and TREM2-deficient BMDMs. (D) Cyclocreatine normalizes ATP
concentration for all conditions, while zymosan greatly boosts ATP concentration in all
conditions. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA with HolmSidak multiple comparisons testing.
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Figure 11. Cyclocreatine treatment partially restores microglia function in TREM2-deficient
5XFAD mice.
(A) Immunoblotting for mTOR targets Akt S473 and NDRG1, as well as LC3-I and LC3-II in
non-treated and cyclocreatine-treated 5XFAD. (B) Microglia number in TREM2-deficient
5XFAD is partially restored to 5XFAD levels with cyclocreatine treatment. (C) The percentage
of microglia expressing activation marker Spp1 is rescued by cyclocreatine treatment. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA with Holm-Sidak multiple
comparisons testing.

50

Table 2. Genes upregulated in 8 month 5xFAD microglia compared to controls.
WT 5xFAD/ctrl TREM2 5xFAD/ctrl
Gpnmb

51.1348009

5.844581907

Spp1

32.80583834

2.161398446

Fabp3

29.91093348

3.927947952

Mamdc2

28.38995648

1.401424397

Cst7

27.18838572

14.19932165

Fabp5

26.92798746

4.081234505

Hpse

22.57314185

5.228671278

Lpl

22.56346182

4.988805449

Egln3

22.37373468

2.73306839

Bhlhe40

19.62798126

1.67423832

Igf1

18.77155118

4.381045471

Itgax

17.85544881

3.226909598

Atp6v0d2 14.944863

1.166452117

Actr3b

12.5927362

2.205279913

Ch25h

12.15845162

2.044315642

Tnfsf9

12.01862098

2.574841367

Clec7a

11.66986089

4.614432883

Etl4

11.3741753

1.903113427

Axl

10.93860924

2.525070146

Cd200r4

10.9067322

3.005780224

Cox6a2

10.36107115

3.434451054

Cd69

10.20685209

3.07515763

Fold change was calculated for both WT and TREM2-deficient mice, and genes are sorted by
greatest fold change. Bhlhe40 is highlighted in red.
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Figure 12. Bhlhe40-EGFP reporter mice have little Bhlhe40 expression in microglia.
The left side shows GFP and Iba-1 co-staining, and the right side shows only the GFP signal
colocalized to microglia. While some colocalization of GFP and Iba-1 is present, it is likely
artifactual as it corresponds to regions of GFP+ neurons.
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Figure 13. Bhlhe40 deficiency does not affect activation state of sorted microglia on the
transcriptional level.
(A) Volcano plot showing Bhlhe40-/-/WT fold change and p-value, with thresholds of differential
expression set at 1.5 fold-change and p<0.05. Only a handful of genes are differentially
expressed with these criteria, including Bhlhe40. (B) Quantile-normalized values of a panel of
genes altered during microglial activation, color-coded within each row (red is higher
expression). Homeostatic and activated microglia genes are expressed in both genotypes at
similar levels.
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Figure 14. Microglia and astrocyte clustering around plaques is altered by Bhlhe40 deficiency.
(A) Representative images of microglia, astrocytes, and Aβ plaques in 5XFAD and Bhlhe40-/5XFAD mice, showing microglia and astrocytes surrounding plaques in both genotypes. (B) The
density of microglia within 20 µm of plaques is higher in Bhlhe40-/- mice. (C) A similar trend is
observed with astrocytes but is more variable.
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Chapter 4: Unbiased screen for TREM2
expression-modifying genes
Given that dose-dependent effects of TREM2 deficiency have been observed in mouse
models of AD40,161,162 and that heterozygosity for TREM2 mutations can increase AD risk,
disease progression appears to be quite sensitive to changes in TREM2 expression. Thus,
modulation of TREM2 expression levels may offer an alternative strategy for harnessing
protective functions of TREM2. Increasing TREM2 expression has the advantage of preserving
the spatiotemporal activation profile of TREM2. For instance, if TREM2 specifically recognizes
amyloid plaque components, then increased TREM2 expression would sensitize plaque-adjacent
microglia to activation while limiting unnecessary inflammation elsewhere. Early work on
TREM2 reported that IL-4 can increase TREM2 surface expression, while LPS or IFNγ can
cause complete loss of expression56. As previously mentioned, the extracellular domain of
TREM2 can be shed by ADAM10 and ADAM17 during steady state, reducing the surface
TREM2 available for intracellular signaling. However, beyond these relatively isolated
mechanisms, little is known about regulation of TREM2 surface expression.

4.1 Design and execution of CRISPR-Cas9 knockout screen
CRISPR-Cas9 knockout library screening has emerged as a powerful, versatile tool for
identifying causal genes and pathways important for various processes. By performing a gene
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knockout screen for TREM2 surface expression, we can obtain a global snapshot of pathways
that regulate TREM2 synthesis, trafficking, and degradation, which has not previously been
attempted. These results would allow us and others to pursue better-targeted therapeutics to boost
TREM2 expression. Furthermore, some of these pathways likely regulate other proteins in
different cell types, and mechanistic understanding of the effect of these genes or pathways on
TREM2 will help to elucidate their effect in general in other systems.
To identify genes that modulate TREM2 surface expression, we used the microgliaderived BV2 cell line, which expresses abundant surface TREM2. We took advantage of a
previously generated set of four independent BV2 CRISPR-Cas9 lentiviral knockout libraries,
each containing one single-guide RNA (sgRNA) per gene targeting a total of 20,077 genes.
These libraries are each subpools of the published Asiago library163. Each clone in this library
contains Cas9, a unique sgRNA, and the corresponding gene ablation. Clones can be isolated
according to phenotypic enrichment, then assayed for genotypic enrichment by amplification and
sequencing of the lentivirally integrated sgRNA. Since surface expression is a cell-intrinsic
phenotype that can be assessed by flow cytometry, we performed a pooled screen whereby cells
staining for relatively higher or lower levels of TREM2 were sorted from the starting library by
FACS to identify enriched sgRNAs. After sorting the 20% highest and 20% lowest TREM2expressing cells, we cultured TREM2-high and TREM2-low cells to equilibrate them and sorted
either the 20% highest or 20% lowest. This process was repeated one additional time, for a total
of three sequential sorts. A portion of cells from each step was harvested for genomic DNA, and
all samples were submitted for amplification and sequencing at the Genomic Perturbation
Platform at the Broad Institute. The master list of hits was assembled in three steps. First, we
calculated fold enrichment of each gene within each subpool as follows: read count values were
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averaged for singly, doubly, and triply sorted TREM2-high or TREM2-low samples, and the
ratio of TREM2-high : TREM2-low was calculated. This method favors sgRNAs that enrich
strongly after multiple sorts but also those that are consistently enriched after each step. Second,
we calculated a modified rank mean for each gene across the four subpools by dropping the
worst rank and averaging the other three. Third, we determined statistical significance by
simulating random rank lists and empirically calculating the chance that a randomly generated
rank list would produce a modified rank mean as good or better than the given modified rank
mean. A cut-off of p < 0.05 was used to select genes for follow-up.
As expected, TREM2 and DAP12 sgRNAs were among the top three most enriched in
TREM2-low populations, while ADAM17 sgRNAs were the most enriched in TREM2-high
populations. Thus, our screen easily detected known modulators of TREM2 surface expression,
and an additional 25 genes had statistically significant rank sums (Table 3). These genes were
validated by lentiviral expression of individual sgRNAs and staining for surface TREM2. The
top-scoring sgRNA for each gene was selected from the four pools and inserted into the
lentiGuide-puro construct, and lentivirus was packaged and transduced into Cas9-expressing
BV2 cells. Due to generation of a heterozygous cell population by CRISPR knockout, each
transduced population, including vehicle-transduced controls, were sorted once for either the
highest or lowest 20% of TREM2 expressers, depending on the direction of change predicted by
the screen, to enrich for clones with the largest effects (presumably homozygous knockouts). For
example, the TREM2 and DAP12 knockout lines were sorted for low expressers, and the
ADAM17 knockout line was sorted for high expressers. These once-sorted lines were then used
to quantify mean fluorescence intensity (MFI) relative to once-sorted empty vector cells. Several
sgRNAs caused statistically significant differences in MFI in the expected direction (TREM2,
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DAP12, DOK1, SLC35A3, NMT1, CRKL, TMEM131), but effect sizes were generally small for
novel genes (Fig. 15). Further validation of these genes with a second, independent sgRNA
confirmed only DAP12, ADAM17, and TMEM131 (Fig. 16A).

4.2 In vitro characterization of TMEM131 effect on
TREM2
We decided, for practical purposes, to focus specifically on the most promising hit,
TMEM131. First, to confirm the specificity of TMEM131 knockout, we used another
independent sgRNA against TMEM131 and demonstrated again increased TREM2 surface
expression. We cloned out TMEM131 cDNA from murine brain tissue and overexpressed a
3xFLAG-tagged version in BV2; TREM2 surface expression decreased, confirming the
specificity of TMEM131 (Fig. 16B). We sought to interrogate the dependence of the TMEM131TREM2 interaction on transcriptional regulation, on species, and on cleavage. First, we treated
various CRISPR-Cas9 knockout lines with the broad metalloproteinase inhibitor GM6001. If
TMEM131 functions by modulating ADAM family metalloproteinases, then in the presence of
GM6001, the difference between TMEM131 knockout and parental BV2 should be reduced.
This treatment increased the TREM2 surface expression in all cell lines, including TMEM131
knockout to a similar extent, making this mechanism less likely (Fig. 16C). Next, we replaced
the stem region of human TREM2 with the stem region of human CD8, which is not cleaved by
ADAM family members. This construct was overexpressed in BV2 cells under control of the
CMV promoter and demonstrated relatively homogeneous and abundant surface expression.
After lentiviral transduction with two independent sgRNAs targeting TMEM131 or empty
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vector, TMEM131 knockout cell lines expressed significantly higher levels of CMV-driven,
cleavage-resistant human TREM2 (Fig. 16D), demonstrating that TMEM131 cross-reacts with
both human and mouse TREM2 and likely does not function through transcriptional regulation
or cleavage of the stem region. Because of the robust expression of the cleavage-resistant
construct and the availability of reagents against human TREM2, we used these cell lines for
subsequent experiments.
Given these results, we hypothesized that TMEM131 likely regulates TREM2 in a posttranslational fashion. First, we investigated if TMEM131 affects the half-life of surface TREM2
by performing a cycloheximide chase. While TMEM131 knockout cells express higher surface
TREM2 at baseline, they lose expression at a similar rate over the course of a two hour chase,
suggesting that TMEM131 does not directly promote degradation of mature surface TREM2
(Fig. 17A).
Because of the unique presence of intramembranous charged residues in TREM2 and
Dap12 that are important for TREM2 trafficking, we investigated whether this feature was
important for TMEM131-TREM2 interaction by generating a TREM2 mutant with a K→A
substitution that ablates the intramembranous charge. This mutation is also expected to abolish
interaction of TREM2 with DAP12. We found that TREM2 K186A surface expression increased
upon TMEM131 knockout similarly to non-mutated TREM2 (Fig. 17B). This demonstrates that
the K186 residue is not required for TMEM131 effect, and most likely, TMEM131 interacts
directly with TREM2 rather than indirectly through Dap12. We performed additional
experiments testing the specificity of TMEM131 effect by measuring surface expression of other
myeloid markers such as CD11b, CD33, CD44, and CD45 with or without TMEM131 knockout.
None of these surface markers were affected, showing that the effect on TREM2 is relatively
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specific (Fig. 17C). These results provide a rough idea of the role of TMEM131 in regulating
TREM2 surface expression and set the stage for future in vivo studies.
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Table 3. List of genes and modified rank mean for statistically significant genes enriched in
TREM2-low or TREM2-high fractions.
sgRNA
enriched
in
TREM2-low
Gene
Rank
mean
Trem2
1

Gene

Pten

Rank
mean
10.33

Rank
mean
1110025L11Rik 54

sgRNA enriched in
TREM2-high
Gene
Rank
mean
Adam17
22

Gene

Dok1

2

Ptpn6

16

Krtap6-5

57.33

Tecr

22.33

Tyrobp

2.67

Pitpnb

18.67

Nadk

74.67

Gne

57.67

Ric8

5.33

Son

20

Nmt1

76.33

Tmem131

66.67

Kctd5

6.33

Ggnbp2 30

Krtap19-2

81.67

Slc35a1

98

Slc35a3

6.67

Dnttip1

32.5

Tec

84.33

Crkl

7.67

Inpp5d

41.67

Fasn

94

Tfap4

8.33

Ppp2r4

44.33
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Figure 15. Statistically significant genes were validated by generating sgRNA knockouts using
the top-ranking sgRNA from the screen.
As expected, TREM2 sgRNA effectively ablates TREM2 surface expression, while DAP12 and
ADAM17 knockout decreases and increases TREM2 surface expression, as expected. Of novel
genes, DOK1 knockout has the largest effect in reducing TREM2 surface expression, while
TMEM131 knockout has the largest effect in increasing it. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 by one-way ANOVA with Holm-Sidak multiple comparisons testing.
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Figure 16. TMEM131 suppresses surface levels of TREM2 through a metalloproteinaseindependent mechanism.
(A) Lentiviral CRISPR-Cas9 knockout of genes passing first-round validation with a second,
independent sgRNA further validates TMEM131 suppression of surface TREM2 level. (B)
Retroviral overexpression of TMEM131-3XFLAG in TMEM131-KO BV2 cells restores normal
TREM2 levels and reduces TREM2 levels further in WT BV2 cells. (C) Treatment of CRISPR
KO BV2 lines with broad metalloproteinase inhibitor GM6001 boosts surface TREM2 levels
across cell lines but preserves the higher relative expression in TMEM131-KO cells. (D)
Cleavage-resistant human TREM2 expressed under CMV promoter in BV2 cells can be
increased by TMEM131-KO with two independent sgRNAs.
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Figure 17. TMEM131 suppression of TREM2 does not involve faster degradation rate or require
the intramembranous charge interactions of TREM2 and DAP12.
(A) Cycloheximide chase shows that surface TREM2 levels fall at a similar relative rate in
control and TMEM131-KO BV2 cells. (B) TMEM131-KO increases expression of cleavageresistant human TREM2 as well as the same construct with the intramembranous charged residue
mutated. (C) Surface levels of other myeloid cell markers are not consistently altered by
TMEM131 modulation, suggesting that the TREM2 effect is somewhat specific.
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Chapter 5: Materials and methods
5.1 Methods for Chapter 2
Family cohort
The National Institute of Mental Health (NIMH) Alzheimer’s Disease Genetics Initiative
Study (1) originally ascertained for the study of genetic risk factors in AD with family-based
methods, was used in the WGS analyses in this study. The basis for ascertainment in the NIMH
collection was the existence of at least two affected individuals within a family, typically
siblings. The complete NIMH study cohort contains a total of 1,536 subjects from 457 families.
For the purpose of this analysis, only subjects of self-reported European ancestry were included,
consisting of 1,376 participants (941 definitely affected and 404 definitely unaffected and the
remainder could not be determined as definitely unaffected or definitely affected) from 410
families.

ADSP Whole-exome replication samples
The whole-exome variant calls (limited to SNVs only) were obtained from the
Alzheimer's Disease Sequencing Project (ADSP) study (Study Accession: phs000572.v6.p4) by
requesting accession authorization through dbGaP. The entire study data consists of whole
exome sequencing data on 5096 cases 4965 controls, and an additional 853 (682 Cases [510
Non-Hispanic, 172 Hispanic]), and 171 Hispanic Control subjects from families that are multiply
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affected with AD. For the purpose of this study, only the subjects with the self-reported
Caucasian ethnicity were included in the replication analysis (n=10449).

Family-based Association Testing
Association analyses of the TREM2 variants in the NIMH-WGS dataset were performed
using the family-based association test (FBAT (4) as implemented in PBAT (v3.6 (5). To
maximize statistical power, we tested AD affection status and age of onset jointly, using the
multivariate extension of the FBAT-approach, FBAT-GEE (6). In order to minimize the multiple
testing problems, we applied the weighted Bonferroni-testing strategy (7), which is an extension
of the VanSteen algorithm (8).

Logistical Regression in Case-Control Whole-exome dataset
Logistical Regression using the binary affection status was performed using PLINK
v1.90 (9). We used the additive model to assess allelic effects of SNPs given by the direction of
the regression coefficient showing the effect of each extra minor allele, i.e. a positive regression
coefficient means that the minor allele increases risk/phenotype mean.

Retroviral transduction.
Wild-type TREM2 and DAP12 were cloned into a pMX vector (10), and the QuikChange
II XL Site-Directed Mutagenesis kit (Agilent) was used to generate variants. Lipofectamine 2000
66

(Thermo Fisher Scientific) was used to transfect Platinum E cells (Cell Biolabs) with 2.5 μg of
each plasmid per 10 μL Lipofectamine 2000 to generate retroviral supernatants, per manufacturer
instructions. After 48 hours and 72 hours, medium from 2B4 NFAT-GFP cultures was replaced
with 0.45μm filtered fresh virus and the cells were spun for 1 hour minutes at 800 x g, after
which additional medium was added. Successfully transduced cells were sorted after 1 week and
again after 2 weeks based on TREM2 staining using a FACSAria II.

Quantitative RT-PCR
RNA was isolated from the indicated cells using TRIzol reagent (Thermo Fisher
Scientific) according to manufacturer’s instructions and concentration was determined using a
Nanodrop (Thermo Fisher Scientific). Reverse transcription was performed using the
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen), and q-PCR was
performed using iTaq Universal SYBR Green Supermix (Bio-Rad) on a Roche LightCycler 96.
Primers

used

were

as

follows

from

5’

to

3’:

human

TREM2

isoform

1

GCATCTCCAGGAGCCTCTTG and TGAGAAAGATGCAGGCCAGG; human TREM2
isoform 2 CGGGATGCTGGAGATCTCTG and TCTCAGCCCTGGAGATGCT; human
DAP12 CCCGGAAACAGCGTATCACT and CGCTGTAGACATCCGACCTC; GAPDH
CCTGGTATGACAACGAATTT
GCAGTACAGCCCCAAAAT

and
and

AGTGAGGGTCTCTCTCTTCC;
AACAAAGTCTGGCCTGTATCCAA;

GGAGGGGGTTGAGGTGTT and TGTGCACTTTTATTGGTCTCAAG;
GAGTGACACTTTCCCAAGATGC
CACTCCAATCGTCCCTACAGT

and
and

HPRT
Actb

murine DAP12

CCTTGACCTCGGGAGACCA;

Spp1

CTGGAAACTCCTAGACTTTGACC;

Gpnmb

67

CATTCCCATCTCGAAGGTGAAA

and

AAATGGCAGAGTCGTTGAGGA;

Cst7

GGAGCTGTACTTGCCGAGC and CATGGGTGTCAGAAGTTAGGC. The delta delta Ct
method was used to calculate expression relative to HPRT, GAPDH, or Actb.

Flow cytometry
The indicated cells were washed in FACS buffer (2% bovine calf serum, 0.01% sodium
azide in PBS), then stained with either isotype control, unconjugated anti-human TREM2
antibody (clones 29E3 and 10B11, hybridoma supernatant), or biotinylated anti-human TREM2
antibody (clone 21E10) in FACS buffer for 15 minutes on ice. After washing 3 times with FACS
buffer, cells were incubated with PE-conjugated goat F(ab’)2 anti-mouse IgG1 (Southern
Biotech cat. no. 1072-09, 1:20) or APC-conjugated streptavidin (Life Technologies cat. no.
S868, 1:20) for 15 minutes on ice. Staining for myeloid cells was performed using BV421-antiCD45 (30-F11, Biolegend, 1:200), FITC-anti-CD11b (M1/70, eBioscience, 1:200), and APCanti-F4/80 (BM8, eBioscience, 1:100). After washing 3 times with FACS buffer, cells were
resuspended in FACS buffer, propidium iodide was added (Sigma-Aldrich, final concentration
5μg/mL), and cells were read on a FACSCalibur. Cells were gated based on forward and side
scatter and propidium iodide negativity.

Reporter assay
Phosphatidylcholine (Avanti, #840051P), phosphatidylserine (Avanti, #840032P), and
sulfatides (Avanti, #131305P) were reconstituted in methanol, methanol, and chloroform :
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methanol : water 2 : 1 : 0.1, respectively. For each experiment, two Nunc-Immuno MicroWell 96
well solid plates (Sigma) were coated with the purified lipid ligands phosphatidylcholine,
phosphatidylserine, or sulfatide by diluting to the indicated concentration in methanol and adding
50μL of the resulting solution to each well, with each condition performed in duplicate. Plates
were allowed to dry by evaporation, leaving the ligands coated on the well bottom. For human
HDL (Millipore) and human LDL (Millipore), stock solution was diluted to the proper
concentration in carbonate buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6) and 50μL of the
resulting solution was added to each well, with each condition performed in duplicate. The plates
were transferred to 4°C overnight. The next day, solution was aspirated from each well, and each
well was washed once with 150μL of PBS. For plate-bound antibody, goat (Fab’)2 anti-mouse
IgG (Southern Biotech, cat no. 1012-01) was diluted 1:100 in carbonate buffer, and 50μL of the
resulting solution was added to wells in triplicate. The plate was placed at 4°C for 12 hours.
Then, solution was aspirated and each well was washed once with 150μL of PBS. 29E3
hybridoma supernatant was plated in each well at 4°C. After 12 hours, the supernatant was
aspirated and wells were washed once with 150μL of PBS.
After preparation of the plate, 50,000 cells in 75μL of complete media were added to
each well. After 12 hours, the cells were transferred to FACS tube and read on a FACSCalibur.
Cells were gated based on forward and side scatter and propidium iodide negativity. The
nontransduced control was used to draw the gate for GFP positivity, and this gate was used to
determine the %GFP+ for each variant and ligand concentration. The average %GFP+ at the
lowest two concentrations for each variant were assumed to be baseline activation, and this value
was subtracted from the curve for each respective variant. The values for all concentrations were
summed to approximate the area under the curve, which was used for analysis.
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Mice
Trem2-/- 5XFAD mice were generated as previously described(Wang et al. 2015). The
CTD-2210D2 bacterial artificial chromosome (BAC) clone was purchased from Thermo Fisher,
and the R47H polymorphism was introduced by recombination using the Quick and Easy BAC
Modification Kit (Gene Bridges). The entire BAC was injected into the nucleus of fertilized eggs
from C57BL/6 x CBA mice, and CV and R47H founders were obtained. The two lines selected
for further work were subsequently backcrossed onto the C57BL/6 background for at least four
generations (some done in the process of crossing to Trem2-/- and 5XFAD mice, both of which
are on a C57BL/6 background). All mice were bred and housed in specific pathogen free
conditions. Animals were sacrificed between the ages of 245-260 days (8.5 months), with each
experimental group containing both transgenic and non-transgenic mice.

Cell culture and biochemical assays
To

obtain

thioglycollate-elicited

peritoneal

macrophages,

mice

were

injected

intraperitoneally with 1 mL of 3% thioglycollate medium (Sigma, prepared in water and
autoclaved), and cells were harvested by peritoneal lavage after 3 days. Cells were subsequently
stained for flow cytometry. To prepare bone marrow-derived macrophages, femurs and tibias
were removed and flushed with PBS. Cells were counted and plated at 2 x 106 cells/100 mm
petri dish in RPMI supplemented with Glutamax, penicillin/streptomycin, nonessential amino
acids, pyruvate, and 10% heat inactivated fetal bovine serum and 10% L-cell conditioned
medium (LCCM) as a source of colony stimulating factor 1 (CSF1). Cells were cultured for 4-6
days before use. Human HDL (Millipore) was supplemented at a concentration of 50 μg/mL.
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RAW264.7 cells were cultured on non-tissue culture treated 12-well plates in RPMI
supplemented with Glutamax, penicillin/streptomycin, pyruvate, and 5% fetal bovine serum.
RAW264.7 cells were transduced with Cas9 overexpression lentivirus and transfected
with plasmid expressing guide RNA against murine TREM2. TREM2-negative cells were sorted
by FACS. lentiCas9-Blast and lentiGuide-Puro were gifts from Feng Zhang (Addgene plasmids
# 52962, #52963, respectively). These TREM2-deficient RAW264.7 were retrovirally
transduced with either CV or R47H driven under the CMV promoter and cells were sorted for
hTREM2 expression by FACS. Cells were stimulated for 30 minutes or 2 hours with 10 ng/mL
LPS (K12, Invivogen), 20 ng/mL recombinant TNFα (Peprotech), or 20 ng/mL recombinant
IFNγ (Peprotech). For sorting Adam17-KO populations, cell were stimulated for 30 minutes with
10 ng/mL LPS and then stained for hTREM2.

Preparation of brain samples
Mice were anesthetized with ketamine/xylazine and perfused with ice-cold PBS
containing 1 U/ml of heparin. Right brain hemispheres were fixed in 4% PFA overnight at 4°C
rinsed in PBS and incubated overnight at 4°C in 30% sucrose before freezing in a 2:1 mixture of
30% sucrose and optimal cutting temperature compound. Serial 40 µm coronal sections were cut
on a cryo-sliding microtome. Cortices and hippocampi of the left-brain hemispheres were
carefully dissected out and flash frozen for biochemical analysis. A portion of cortex was
preserved in RNAlater (Ambion) until all samples were collected.
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Confocal microscopy
Floating sections were blocked with 3% bovine serum albumin and 0.25% Triton X-100
in PBS, and then stained with anti-Iba-1 (rabbit polyclonal, Wako, 1:5000; or goat polyclonal,
Abcam 1:1000), anti-human TREM2 ECD (goat polyclonal, R&D, 1:500), anti-human TREM2
C-terminus (D814C rabbit mAb, Cell Signaling, 1:500), anti-Spp1 (goat polyclonal, R&D,
1:500), anti-APP (22C11 mouse mAb, Millipore, 1:1000) and/or anti-NeuN (D3S3I rabbit mAb,
Cell Signaling, 1:500) overnight at 4°C followed by staining with anti-rabbit IgG DyLight 549
(Vector, 1:2000), anti-goat IgG AlexaFluor-488 (Abcam, 1:2000), anti-rabbit IgG AlexaFluor647 (goat polyclonal, Invitrogen, 1:1000), anti-goat IgG-biotin (donkey polyclonal, Invitrogen,
1:2000), streptavidin AlexaFluor-647 (Invitrogen, 1:2000), methoxy-X04 (Tocris, 3 μg/mL),
and/or TO-PRO-3 iodide (Thermo-Fisher, 300 nM) for 1 hour at RT. All antibodies were used in
blocking buffer, and between all incubations, sections were washed for ten minutes in PBS three
times. Images were collected using a Nikon A1Rsi+ confocal microscope. 3D image
segmentation of microglia, plaques, and neurons, and extraction of parameters were performed in
Imaris 8.1 (Bitplane), and further processing was performed using automated scripts in Matlab
(Mathworks). For detailed image analysis procedures, see Supplementary Methods.

Immunoblot
Samples were prepared from PBS-soluble or PBS-insoluble guanidine-soluble fractions
of brain homogenates (as described above), or from cell lysates, by adding 1X NuPAGE LDS
sample buffer (Invitrogen) and 10% β-mercaptoethanol and boiling for 5 minutes. Samples were
run on NuPAGE 4-12% Bis-Tris pre-cast gels (Invitrogen), transferred to nitrocellulose
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membranes, and blocked with 5% milk in PBS+0.05% Tween-20 (PBS-T) for 1 hour at room
temperature. Membranes were incubated with in-house generated 29E3 anti-human TREM2
antibody (mouse IgG1, 4 μg/mL), anti-TACE/ADAM17 (rabbit polyclonal, Novus, 1:1000), or
anti-pan-actin (rabbit polyclonal, Cell Signaling, 1:4000) in 0.5% milk/PBS-T overnight at 4°C,
and incubated in HRP-conjugated anti-rabbit Ig (goat polyclonal, Southern, 1:1000) or HRPconjugated anti-mouse IgG1 (goat polyclonal, Southern, 1:1000) at room temperature for 1 hour,
with 3 washes of PBS-T between steps. Blots were detected by SuperSignal West Pico
Chemiluminescent Substrate or SuperSignal West Femto Maximum Sensitivity Subtrate
(Thermo) with autoradiographic film. Developed films were scanned using an Epson Perfection
V370 Photo scanner and analyzed using Image Studio Lite (LI-COR).

qRT-PCR and microarray analysis
For microarray analysis of sorted microglia, perfused brains were homogenized using the
Neural Dissociation Kit (T) (Miltenyi) per manufacturer instructions. The homogenized tissue
was run through a 70μm cell strainer and resuspended and centrifuged in 30% Percoll (GE). The
resulting pellet was stained for CD11b and CD45, and CD11b+CD45+ cells were sorted using a
FACSAriaII. RNA was extracted from sorted cells using the RNeasy Micro Plus kit (Qiagen) per
manufacturer instructions and submitted for microarray analysis at the Genome Technology
Access Center at Washington University. Samples were amplified using the Nugen Ovation Pico
SL and run on the Affymetrix Gene 1.0 ST platform.
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Statistics
Data in figures are presented as mean ± SEM. Unless otherwise stated, statistical analysis
was performed using Prism (GraphPad). Statistical analysis to compare the mean values for
multiple groups was performed using a one-way or two-way ANOVA, as appropriate, with
Holm-Sidak multiple comparisons testing.

5.2 Methods for Chapter 3
Mice
The generation of Trem2–/– and Trem2–/– 5XFAD mice has been described previously
(Oakley et al., 2006; Turnbull et al., 2006; Wang et al., 2015). All mice were on a C57BL/6
background. Age and sex matched mice were used for all experiments; experimental cohorts of
mice were cohoused from birth to control for the microbiota.. For in vivo cyclocreatine treatment
10-week old mice were put on cyclocreatine-containing water, treatment was continued until
mice reached 8 months of age (Santa Cruz SC-217964 S). Desired intake of cyclocreatine was
approximately 0.28 mg/g of body weight/day, which is approximately the same as the standard
creatine dose used in humans of 285 mg/kg of body weight/day164. Cyclocreatine was
administered in drinking water at a final concentration of 2.33 mg/ml. Bhlhe40-EGFP and
Bhlhe40-deficient mice have previously been described165. The Institutional Animal Care and
Use Committee at Washington University in St. Louis approved all protocols used in this study.

Cell culture and biochemical assays
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To prepare bone marrow-derived macrophages, femurs and tibias were removed and
flushed with PBS. Cells were counted and plated at 2.5 x 106 cells/100 mm petri dish in RPMI
supplemented with Glutamax, penicillin/streptomycin, nonessential amino acids, pyruvate, and
10% heat inactivated fetal bovine serum (complete RPMI) and 10% L-cell conditioned medium
(LCCM). Cells were cultured for 4-5 days before use. ATP concentrations were determined with
an ATP Determination Kit (Invitrogen).

Microglia sorting
Microglia were isolated from the indicated animals as previously described (Wang et al.,
2015). CD45+, CD11b+, F4/80+ (Biolegend Cat. Number 103134, eBioscience Cat. Numbers
11-0112 and 17-4801) cells in the brain were fluorescence-activated cell-sorted (FACS) directly
into RLT-plus lysis buffer for microarray or 2% FBS in PBS for TEM or immunoblot lysates.
For microarray RNA extraction was performed using a RNeasy micro kit (QIAGEN).
Microarray hybridization (Affymetrix MoGene 1.0 ST array) and data processing were
performed at the Washington University Genome Center.

Immunoblotting
BMDM or microglia were lysed in RIPA buffer (50 mM Tris, 150mM NaCl, 1% SDS,
and 1% Triton X100) containing PMSF, leupeptin, activated sodium orthovanadate, apoprotinin,
and phosphatase inhibitor cocktail 3 (Sigma Aldrich Cat. Number P0044). Lysates were flash
frozen on dry ice and stored at -80o C until use. Lysates were thawed and 4x LDS running buffer
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and 10% β-mercaptoethanol were added. Lysates were heated to 95o C for 10 minutes and run
on either a 15 % polyacrylamide gel with a 4% stacking gel, a 12% bis-tris gel (Nupage), or a 412% bis-tris gel (Nupage). Proteins were transferred to nitrocellulose and blocked for 1 hour at
RT in 5% milk in Tris buffered saline with 0.05% Tween 20 (TBST). Membranes were
incubated in primary antibody overnight at 4o C (Supplemental Table 2). Membranes were
subsequently washed and incubated in Leinco anti-rabbit HRP for 1 hour at RT, washed, and
developed using either SuperSignal West Pico Chemiluminescent Substrate or a combination of
SuperSignal

West

Pico

Chemiluminescent

Substrate

and

SuperSignal

West

Femto

Chemiluminescent Substrate.

Metabolism assays
For real-time analysis of extracellular acidification rates (ECAR) macrophages were
analyzed using an XF96 Extracellular Flux Analyzer (Agilent Technologies). Cells were
incubated overnight in complete RPMI in the indicated concentration of LCCM with or without
cyclocreatine (10 mM). Measurements were taken under basal conditions and following the
sequential addition of 1 μM oligomycin and 1.5 μM fluoro-carbonyl cyanide phenylhydrazone
(FCCP) (purchased from Sigma-Aldrich).

Transmission electron microscopy
For ultrastructural analyses, cells were fixed in 2% paraformaldehyde/2.5%
glutaraldehyde in 100 mM sodium cacodylate buffer, pH 7.2 for 1 hr at RT (Polysciences Inc.,
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Warrington, PA). Samples were washed in sodium cacodylate buffer and postfixed in 1%
osmium tetroxide for 1 hr (Polysciences Inc.). Samples were then rinsed extensively in deionized
water prior to en bloc staining with 1% aqueous uranyl acetate for 1 hr (Ted Pella Inc., Redding,
CA). Following several rinses in dH20, samples were dehydrated in a graded series of ethanol
and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica
Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl
acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope
(JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT
Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA). For
quantitation of multivesicular/multilamellar structures, 30 cells that were cross-sectioned through
the nucleus (indicating cross-section through the middle of cell) were randomly chosen, and
images of each cell were taken at 6,000X and 20,000X magnification. The cross-sectional area of
each of the multivesicular structures were determined using Image J 1.38g (National Institutes of
Health, USA, customized for AMT images). Data is expressed as the 1) total number of a
multivesicular/multilammelar structures per cross sectional area of cytosol and 2) the total crosssectional area of multivesicular/multilamellar structures per area of cytosol.

Preparation of brain samples and confocal microscopy
Confocal microscopy analysis was preformed as previously described (Wang et al.,
2015). Briefly, mice were anesthetized with ketamine/xylazine and perfused with ice-cold PBS
containing 1 U/ml of heparin. Brains were fixed in 4% PFA overnight at 4o C rinsed in PBS and
incubated overnight at 4o C in 30% sucrose before freezing in a 2:1 mixture of 30% sucrose and
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optimal cutting temperature compound. Serial 40 μm coronal sections were cut on a cryo-sliding
microtome. Floating sections from 1.1 mm Bregma to 0.8 mm Bregma for cortical imaging were
stained with Iba-1 (Waco Chemicals Cat. Number 019-19741) overnight at 4o C followed by
staining with anti-rabbit IgG DyLight 549 (Vector Laboratories Cat. Number DI-1549) and
methoxy-X04 (Tocris Cat. Number 4920) for 1 hour at RT. Images were collected using a Nikon
A1Rsi+ confocal microscope. Images were then processed with Imaris 7.7 (Bitplane).

Microglia clustering analysis
Positions of microglia and positions and volumes of plaques within z-stacks were derived
from analysis in Imaris, and microglia-plaque association was determined using automated
scripts in Matlab. Briefly, each plaque in the z-stack was modeled as an idealized sphere with the
same volume and center of mass. Microglia density within 15 or 20 μm of the plaque surface was
determined by isolating the voxels of the image that fall within 15 or 20 μm of the edge of the
idealized plaque. The number of microglia contained in these voxels was divided by the total
volume of those voxels to obtain density for a single plaque. Densities of all plaques in a z-stack
were averaged together, and the resulting values were averaged together for all z-stacks
corresponding to a single animal.

Reporter cell assay
The 2B4 T cell hybridoma cell line was retrovirally transduced with an NFAT-GFP
reporter construct, and TREM2 reporter cells were generated by a second retroviral transduction
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with a TREM2 overexpression construct and selected by puromycin resistance, as previously
described (Wang et al., 2015). Cells were cultured routinely in complete media (10% FBS in
RPMI-1640 supplemented with sodium pyruvate, GlutaMAX, and penicillin/streptomycin). For
serum starvation, cells were plated at a density of 25,000 cells/well in a 96-well plate in either
complete media or RPMI-1640 in the presence of 20% anti-TREM2 hybridoma supernatant
(clone M178, generated in house) or 20% isotype control hybridoma supernatant (Wang et al.,
2015). After 16 hours, the percent of GFP+ cells among live cells was measured by flow
cytometry.

5.3 Methods for Chapter 4
Library preparation and screening
BV2 cells were transduced with Cas9 overexpression lentivirus lentiCas9-Blast, selected
by blasticidin treatment to obtain BV2-Cas9 cells. These cells were subsequently transduced
with lentiGuide-Puro Asiago library subpools 1, 2, 5, or 6163 and selected by puromycin
treatment to generate 4 independent genome-wide knockout libraries. Each library was divided
into two batches as technical replicates. Three sequential sorts were performed for each library
by sorting the top or bottom 20% of TREM2-expressing cells multiple times with two days of
equilibration in culture between sorts. Specifically, TREM2-high cells were sorted again for the
top 20% to generate TREM2-high-high cells, while TREM2-low cells were sorted again for the
bottom 20% to generate TREM2-low-low cells, etc. After each sort, a portion of the cells was
harvested for DNA extraction, such that we assayed all combinations of different libraries and
different numbers of sorts. A fraction of cells was maintained in culture for the same duration of
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time without sorting to serve as a control. These samples were submitted to the Genetic
Perturbation Platform at the Broad Institute for amplification and deep sequencing.

Cell culture
All BV2-derived cell lines were cultured in 5% FBS in RPMI supplemented with
GlutaMAX, sodium pyruvate, and penicillin/streptomycin. BV2-Trem2-KO

cells

were

previously generated by CRISPR-Cas9 followed by sorting of TREM2-negative cells. These
TREM2-deficient BV2 were retrovirally transduced with pMX vectors carrying cleavageresistant hTREM2 (hTREM2-CD8, residues 133-174 of hTREM2 replaced with the sequence
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD from CD8 stem region)
or hTREM-CD8 with an additional point mutation (K186A), followed by IRES and human
DAP12. Lentivirally-mediated CRISPR-Cas9 knockout was performed by cloning the
appropriate sgRNA sequence into either the lentiGuide-Puro or lentiCRISPRv2-Blast vectors.
TMEM131 was cloned from cDNA derived from mouse brain, and the obtained sequence
corresponded to the predicted isoform X2. This fragment was inserted into the pMX-IRES-puro
vector with a C-terminal 3XFLAG tag. Cycloheximide was used at a concentration of 25 µg/mL.
GM6001 was used at a concentration of 10 µg/mL.

Flow cytometry
Cells were washed in FACS buffer (2% bovine calf serum, 0.01% sodium azide in PBS),
then stained with either isotype control, unconjugated anti-human TREM2 antibody (clones
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29E3 or 21E10, hybridoma supernatant), or in FACS buffer for 15 minutes on ice. After washing
3 times with FACS buffer, cells were incubated with PE-conjugated goat F(ab’)2 anti-mouse
IgG1 (Southern Biotech cat. no. 1072-09, 1:20) or PE-conjugated goat anti-rat IgG (Southern
Biotech cat. no. 3030-09) for 15 minutes on ice. Staining for other myeloid markers was
performed using FITC-anti-CD44 (eBioscience, 1:200), PE-anti-CD64 (eBioscience, 1:200),
FITC-anti-CD45 (30-F11, eBioscience, 1:200), FITC-anti-CD11b (M1/70, eBioscience, 1:200),
and PE-anti-F4/80 (BM8, eBioscience, 1:100). After washing 3 times with FACS buffer, cells
were resuspended in FACS buffer, propidium iodide was added (Sigma-Aldrich, final
concentration 5μg/mL), and cells were read on a FACSCalibur. Cells were gated based on
forward and side scatter.
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